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Over expression of Sperm Acrosomal SLLP1 Binding protein (SAS1B) on the 
surface of uterine cancer and the availability of different anti-SAS1B monoclonal 
antibodies (mAbs) that specifically bind to it, offered an opportunity to label these 
antibodies with radionuclides for cancer imaging. Although optimizing in vivo stable 
radiolabeling is challenging, imaging this type of aggressive cancer will improve the 
treatment strategy.  The objective of this work is to develop a radiolabeled anti-SAS1B 
antibodies with Zircunum-89 (89Zr) and Copper-67 (67Cu) and determine, in vitro and in 
vivo their uptake and biodistribution. Two anti-SAS1B monoclonal antibodies (SB2, and 
SB5) were labeled indirectly with 89Zr and 67Cu, using Deferoxamine (DFO) and Para 
Isothiocyanatobenzyl-1, 4, 7, 10-tetraazacyclododecane tetra acetic acid (p-SCN-Bn- 
DOTA) respectively.  Different molar ratios of anti-SAS1B to the linker were investigated 
for conjugation, (1:3, 1:5, or 1:10) to determine the optimum conjugation molar ratio to 
take forward for labeling.  The optimized conjugate was used to produce a radiolabeled 
mAb which was used for both in vitro cell uptake experiments and in vivo tumor imaging 
and biodistribution study.  Results show specific uterine cancer cell uptake of radiolabeled 
xxi 
SB2 and SB5 indicating the specificity of anti-SAS1B to its target SAS1B surface antigen 
expressed on SNU539 uterine cancers cells.  
[89Zr]-DFO-SB5 PET imaging revealed uptake in the SNU539 tumor xenograft, 
albeit with minimal uptake. Uptake was also observed in bones and this is more likely due 
to detachment of the 89Zr from DFO, and subsequent accumulation in bone. The 
biodistribution profile from imaging data was reflected in the ex vivo biodistribution of 
[89Zr]-DFO-SB5. 
The second mAb SB2 was radiolabeled indirectly using [67Cu]-DOTA and such radio-
conjugate was used to assess its uptake by SNU539 and Sk-OV3 cancer cell lines, which 
express SAS1B antigen.  The [67Cu]-DOTA-SB2 was taken up by both cell lines and this 
uptake was significantly higher than that of 67CuCl2 or [67Cu]-DOTA, indicating more 
specific uptake in the case of radiolabeled Mab.  
             In the absence of radionuclides, the MAb SB2 was conjugated to the near-infrared 
(NIR) fluorescence dye (IR800CW) to enable the potential for optical imaging. Using 
fluorescence microscopy, SB2 mAb labeled with the NIR dye showed more binding to 
SNU539 and Sk-OV3 and no binding to A549, which is consistent with its lack of SAS1B 
expression. Presence of fluorescence signals in uterine cancer cells that express SAS1B 
surface antigens compared with cells do not express SAS1B as negative control. 
               The labeled anti-SAS1B antibodies SB2 and SB5 were evaluated in vitro and in 
vivo. The results demonstrated the specific binding of both labeled antibodies to the surface 
uterine cancer receptors (SAS1B) through in vitro cell uptake and in vivo tumor uptake.  
 
xxii 
Labeled anti-SAS1B mAbs with radionuclides or fluorescent probes could yield an 
imaging version of the mAb that can be used to determine SAS1B receptor status in such 
tumors.  Such determination could impact more individualized treatment of SAS1B-
expressing cancers. 

















































       The challenge of accurate whole-body cancer detection and reporting on biological 
changes, for example changes in tumor metabolic activity, has empowered the development of 
molecular imaging paradigms. These approaches are capable of studying the biology underlying the 
progression of disease and its response to therapy. Over the last two decades, molecular imaging has 
played an important role in the management of cancer patients, aiding in early detection, accurate 
staging, and objective monitoring of response to treatment [1]. A number of molecular imaging 
modalities have been used to support cancer diagnosis and therapy. These include SPECT, PET, 
MRI, and optical imaging using fluorescence or bioluminescence. These modalities have the 
capabilities to image multiple targets using affinity probes labeled with different radioisotopes or 
fluorescence agents. Radioisotopes based imaging engages three important components: 
radioisotope, carrier, and binding target. Many radioisotopes have been used for imaging and 
therapy, based on their specific properties [3]. Developments in antibodies production and 
engineering has led to the availability of antibodies against a variety of targets, such as growth 
factors, cytokines, and cell surface receptors, making antibodies useful in molecular imaging in a 
variety of disease models [4] [5]. Targeted antibodies for tumor imaging are a promising approach 
to evaluating and improving cancer therapy [6].  More than 70 such antibodies were approved by the 
FDA for clinical use [5]. Many human tumors overexpress a variety of surface cell receptors which 
have been used as a basis of receptor-targeted imaging [7]. Tumor receptor imaging offers valuable 
information, including evaluation of the entire tumor burden as well as characterization of the 
heterogeneity of tumor receptor expression. Tumor receptors have been some of the earliest targets 
for tumor imaging and therapy with notable successes in cancer therapy and imaging, for example, 
endocrine-related cancers such as breast, prostate, and thyroid cancers. The high affinity of 




strategies [8].  An advantage of labeling antibodies is their well-defined structure with an abundance 
of functional amino acids capable of binding to modified functional groups of a linker used for 
labeling antibodies indirectly by radionuclides [9].  Although there is potential in using radiolabeled 
antibodies for imaging and therapy, it is still challenging to synthesize a high yield of radiolabeling 
stable in vitro and in vivo [10] [11]. Many factors can affect antibody conjugation, labeling, and in 
vivo biodistribution [12].   
    A novel tumor-selective cell surface biomarker, SAS1B (sperm acrosomal SLLP1 binding 
protein), has been discovered and patented at University of Virginia (UVA) [13]. Initially, SAS1B 
was found to be expressed on ovary and oocytes and was restricted among adult tissue [14],[15]. In 
addition, SAS1B was not detected in a variety of additional normal human tissues and no ASTL 
expressed sequence tags have been deposited in the NCBI Unigene database from normal tissues 
[13] [14]. Studies in vitro identified that the SAS1B target is overexpressed on the surface of a wide 
range of aggressive malignancies such as uterine, ovarian, pancreatic, and renal cancers [13]. 
Different Anti-SAS1B mAbs were designed at UVA and investigated for targeting SAS1B 
expressed on the surface of cancer cell lines [16]. Anti-SAS1B antibodies provide an attractive 
molecular target to develop highly tumor-specific radio-immuno-pharmaceuticals.  
     In this project, two mAbs (SB2 and SB5) were selected for labeling with radionuclides 
Zirconumm-89 (89Zr) and cooper-67 (67Cu) and used in vitro and in vivo work. The work described 
here builds on the development of anti-SAS1B mAbs, carried out in our collaborator’s laboratory at 
UVA, by developing a radiolabeled version of the SAS1B mAb (SB2 and SB5) and investigating its 
targeting credentials and overall pharmacokinetics in vivo animal tumor model of uterine cancer. 
This is being investigated through both ex vivo biodistribution and in vivo molecular imaging 




1.2 Hypothesis  
 
SAS1B antigen has been shown (in vitro) to be overexpressed on the surface of a number of 
aggressive malignancies, including uterine, ovarian and pancreatic cancer. Monoclonal antibodies 
have been produced against SAS1B target antigen. We hypothesize that the development of a 
radiolabeled version of the MAbs would serve as a tool to study the binding of the radiolabeled Mab 
to SNU539 tumors expressing SAS1B in vivo.     
The overall objective is to evaluate the biological behavior and targeting of radiolabeled 
anti-SAS1B mAb (SB2/SB5) in uterine cancer xenografts expressing the SAS1B protein.  In order 
to achieve this, a stable radioimmunoconjugate has to be developed and characterized. Both PET 
and SPECT radionuclides will be used to produce radioimmunoconjugates that can be evaluated by 
in vivo molecular imaging. The in vivo results obtained will complement the information obtained 
from in vitro assays and unravel the kinetics of delivery, retention, and clearance following IV 
administration of the radiolabeled conjugate.  This objective will be investigated through the 
following specific aims. 
1.3 Specific Aims. 
1.3.1 Aim 1: Conjugation and Radiolabeling 
 
The production of radiolabeled anti-SAS1B mAbs involves two steps: i) conjugation of the 
bi-functional chelate to the mAb through covalent attachment; and ii) radiolabeling of the 
conjugated mAb by the radionuclide. Radiolabeled conjugates were evaluated by High-performance 
liquid chromatography (HPLC) with UV and Radio-detection (radio-HPLC) in terms of reaction 
yields, radiochemical and chemical purity. Radio-TLC was used to determine radiolabeling yield 
and determine radiochemical purity, and this method will be validated by the radio-HPLC data.  




to separate the radiolabeled mAb from low molecular weight species, such as free radionuclide and 
non-mAb associated radioactive signal.  
1.3.2 Aim 2: In Vitro Evaluation 
 
The in vitro cell uptake and retention of the radiolabeled mAb will be evaluated using 
uterine cancers cell lines SNU539 (Seoul National University) which is expressing the SAS1B 
protein expressed in the SAS1B.)  Uptake kinetics was determined by incubating the radiolabeled 
mAb and measuring the radioactivity, as a function of time, using radiotracer analysis. The 
immunoreactive fraction of the radiolabeled mAb will also be evaluated and compared to that of the 
unlabeled mAb, in order to determine the effect of radiolabeling on the immunoreactivity of the 
mAb.  
1.3.3 Aims 3: In Vivo Evaluation  
SNU539 uterine cancer cells will be implanted subcutaneously in nude mice and allowed to 
grow to produce xenografts, as tumors expressing the SAS1B target protein.  The radiolabeled mAb 
against SAS1B antigen will be evaluated in this model using either PET or SPECT live animal 










































According to the WHO, cancer is a leading cause of death worldwide. There were about 
10 million deaths in 2020 and the estimation of new cases in 2021 was about 17 million 
worldwide. The American Cancer Society estimates that in 2021, approximately 1,898,160 
Americans will be diagnosed with cancer and of those, approximately 608,570 are expected to 
die [2].  Poor outcomes from the disease are exacerbated by a combination of failure to detect 
cancer until too late and ineffective treatment options [3]. 
Cancer is a broad term describing a large group of diseases that result when cellular 
changes cause the uncontrolled growth and division of cells with the ability to infiltrate and 
destroy normal body tissue. Normal cells have a specific life cycle, growth, division, and death 
in a manner which is determined by the type of cell. A cell receives instructions to die through a 
natural and beneficial phenomenon called apoptosis, which allows the body to replace it with a 
newer cell that functions better [4]. Cancer disrupts the apoptosis process. Cells continue to 
divide without stopping. Most cancers begin as a result of changes or mutations in the gene 
which happen over a person’s lifetime, such as errors occurring during cell division or damage 
to DNA caused by certain environmental exposures to chemicals, certain radiation, and specific 
viruses [5]. Cancer can sometimes begin as a result of faulty genetic changes inherited and 
passed down in families, but this is rare. Depending on the type of cancer, some involve rapid 
cell growth while others grow and divide at a slower rate. Cancers are named based upon the 
area where they begin and the types of cells they produce. Some forms of cancer result in visible 




Although advances are being made in the area of cancer diagnosis, treatment options are still 
limited [6]. 
2.2 Cancer Imaging 
Imaging plays an important role in  comprehensive cancer care with  many advantages 
including real time monitoring, accessibility without tissue destruction, minimal or no 
invasiveness, and the ability to function over wide ranges of time and size scales involved in 
biological and pathological processes [7]. The major contributors to a reduction in mortality for 
certain cancers are early detection and monitoring the treatment of cancer through screening 
based on imaging [8]. The development in molecular imaging increases imaging speed to match 
that of physiological processes [9]. For instance FDG-PET, and subsequently FDG-PET/CT, has 
become a keystone in several oncologic procedures such as tumor staging and restaging, 
treatment efficacy assessment during or after treatment end and radiotherapy planning [10]. 
Image guided and targeted minimally invasive therapy has the promise to improve outcome and 
reduce collateral effects [11]. The research activities in targeted imaging of receptors, gene 
therapy expression, and cancer stem cells have been increased and this might translate into 
clinical use in the next decades [7],[12]. Close collaboration between academia and 
biotechnology, information technology and pharmaceutical industries will lead to development of 









2.3 Cancer Treatment Modalities 
 
Currently there are many modalities for cancer treatments, and appropriate applications 
depend upon the specific type of cancer [13]. Established treatment approaches include surgery, 
chemotherapy, and radiotherapy. Chemotherapy and radiotherapy have been employed for many 
years to kill cancer cells, but in most cases the treatment is more effective in prolonging survival 
[14].Therefore, many cases require a combination of treatments, such as surgery with 
chemotherapy and/ or radiation therapy [15]. Despite dose-limiting toxicity and low specificity, 
prolonged survival has been achieved for many cancer patients [16]. Unfortunately, many 
patients ultimately die due to cancer recurrence, severe side effects of the treatment, or a 
combination of both. A number of therapeutic approaches have been proposed in order to 
minimize the chances of relapse in cancer patients [17]. These include hormone-based therapy, 
gene therapy, cell-based therapy including stem cell therapy, and immunotherapy [18],[19]. 
Cancer treatment based on immunotherapy has been introduced to specifically target cancer 
cells and minimize side effects induced by conventional treatment [20]. 
2.3.1 Surgery 
 
Surgery has been the first standard of care for cancer diagnosis and treatment for more 
than a century [21]. Surgery to establish diagnosis is usually done through a procedure in which 
a small piece of tissue is removed and sent to a histopathology laboratory where it is examined 
for the presence of cancer cells, type of cancer cells, and the stage. When cancer is diagnosed in 
the early stages, surgery to remove the tumor could be the best option and completely curative 
[22]. However, surgery is the only option for a solid tumor and local treatment. Therefore, the 
use of surgery is dependent on the location of the tumor and the stage. When the cancer is late 




the only option for treatment, and in most cases, the cancer is not completely curative [22]. 
Sometimes surgery is done to prevent cancer when the patient is at high risk for a particular type 
of cancer based on family history and genetic studies [23].  For example, surgery to remove a 
breast would be appropriate in a woman with a high risk of breast cancer [24]. Also, surgery 
could be done to treat a problem caused by advanced cancer. This is called palliative, or 
supportive, surgery and is used along with other treatments to correct a problem that is causing 
additional discomfort or disability [25]. For instance, surgery done to remove a blockage in the 
abdomen when the cancer has grown large enough to block (obstruct) the intestine. In some 
cases, palliative surgery is done to treat pain when the pain is hard to control with medicine 
alone. In most cases when cancer is in the late stages, surgery is done not to treat or cure the 
cancer but to bring relief and help the patient to feel better. 
2.3.2 Chemotherapy 
Chemotherapy uses chemical agents (anti-cancer or cytotoxic drugs) to inhibit vigorously 
growing malignant cells [26]. Chemotherapy is a systemic method and, in most cases, is 
recommended for cancer that has already spread to other areas of the body. Chemotherapy drugs 
interact with cancer cells through different ways. Some of the drugs interfere primarily with 
DNA synthesis and mitosis (cell cycle phases M and S), while other drugs work by preventing 
cells from dividing [27]. Based on their chemical structures and the way they act, chemotherapy 
agents divide into different categories.  Alkylating agents were the first anti-cancer drugs used 
and the most commonly-used anticancer drugs in chemotherapy [28]. These agents act during all 
phases of the cell cycle, directly on DNA, causing cross-linking of DNA strands, abnormal base 
pairing, or DNA strand breaks, thus preventing the cell from dividing [29]. Antimetabolites are 
agents altering the function of enzymes required for cell metabolism and protein synthesis by 




are derived from plants and are called plant alkaloids. They specifically block the ability of a 
cancer cell to divide and become two cells [31]. Other chemotherapy drugs called antitumor 
antibiotics act by binding with DNA and preventing RNA (ribonucleic acid) synthesis [32]. The 
cytotoxicity of chemotherapy drugs affects both cancer cells as well as normal cells. The drugs 
destroy cells that divide rapidly under normal circumstances such as digestive tract, cells in bone 
marrow and hair follicles [33],[34]. This effect is not permanent, however, as normal tissues are 
able to repair themselves and continue to grow. The most common absorbed side effects are 
mucositis (inflammation of the lining of the digestive tract), alopecia (hair loss), and 
myelosuppression (decreased production of blood cells, hence also immunosuppression).  
There are different plans to treat cancer cases. In some cases chemotherapy is used as the primary 
treatment, such as in Hodgkin's disease, leukemia, Burkitt's lymphoma, localized diffuse large cell 
lymphoma, Wilms' tumor, small cell lung cancer, and testicular cancer [21]. Sometimes 
chemotherapy is combined with other cancer modalities to increase the effectiveness of treatment. 
For example, chemotherapy is given prior to or after other treatments such as surgery or 
radiotherapy as an adjuvant treatment to shrink the tumor and make it easier to resect. Adjuvant 
chemotherapy is also used to reduce the risk of recurrence or prolong survival. When cure is not 
possible, chemotherapy may be given as palliative therapy for the purpose of helping to make the 










Radiotherapy remains an important modality among the standards of care for cancer 
treatment.  More than fifty percent (50%) of all cancer patients receive radiotherapy during their 
course of illness [36]. Radiotherapy uses ionizing radiation and produces free radicals to kill 
cancer cells and shrink tumors. This is accomplished by damaging the cell structure and DNA in 
the cell nucleus, hence, reducing cell proliferation [37]. The most common way to deliver 
radiation to cancer cells is through external beam radiation therapy. However, only limited 
tumors can be irradiated by high-energy x-rays delivered by a beam to the main tumor [38]. An 
alternate way using brachytherapy to deliver radiation is through internal radiation therapy, 
which is done by using a solid source such as seeds, ribbons, or capsules which contain a 
radiation source and placing them in the body near the tumor [39]. This is also limited to specific 
type of cancer and is similar to external beam therapy. The other method to provide internal 
therapy is through systematic therapy when the source of the radiation is in liquid form, allowing 
the treatment to travel in the blood to tissues, seeking out and killing cancer cells. Additionally, a 
more specific approach for cancer irradiation is provided by targeted radionuclides which utilize 
monoclonal antibodies as a vehicle and bind to specific cancer cell antigens [40]. This increases 
the therapeutic effects of antibodies and minimizes the side effects of nonspecific targeting. 
Radionuclides emit therapeutic radiation such as alpha, beta particles, and Auger electron which 
damage the DNA and cell content with different density of energies [41] (Figure 1). Although 
radiation damages both normal cells and cancer cells, the goal of using targeted radionuclides is 
to maximize the radiation dose to abnormal cancer cells, while minimizing exposure to normal 
cells which are adjacent to cancer cells or in the path of the radiation [42]. Normal cells usually 
can repair themselves at a faster rate and can retain normal function status faster than cancer 




by radiation treatment, which results in differential cancer cell killing.  
 
 
Figure 1. Direct and indirect effect of ionizing radiation on the cell DNA. 
 
2.3.4 Targeted and Biological Therapy 
 
Conventional therapies such as radiation, chemotherapy, and surgery have been used as 
standard care of cancer treatment for many years [43]. In addition to their potential to kill cancer, 
however, there are significant side effects on healthy surrounding tissues and organs [44]. Therefore, 
scientists and researchers have been working to discover methods of treatment that are capable of 
killing only cancer cells while not affecting healthy tissues at the same time. As scientists and 
researchers gain a better understanding of the mechanisms and metabolisms of the cells, such as 
how they replicate, become malignant, their methods of obtaining the nutrients that allow them to 




drugs which would stop the growth of, or even kill, very specific cells such as those that have 
become cancerous [45]. This process is referred to as “targeted therapies.”  It involves the use of 
very specific methods which interfere with some aspect of cellular life while not harming healthy 
cells. In cases where biological molecules are used, these therapies are sometimes called 
“molecular-targeted drugs.”[46]. 
 Biological therapy uses the body’s immune system, either directly or indirectly, to 
specifically kill cancers cells or minimize the side effects that may be caused by cancer treatments 
[47]. Biological therapy includes immunotherapy (such as vaccines, cytokines, and some 
antibodies), gene therapy, hormone therapy, and some targeted therapies [48].  
2.3.5 Immunotherapy 
Cancer immunotherapy has emerged as a promising approach to therapy [49]. 
 
Immunotherapy approaches include the use of monoclonal antibodies (mAbs), cancer vaccines, 
adoptive cancer therapy, and the immune checkpoint blockade therapy [50]. In the past decade, 
cancer immunotherapy has become a new pillar of cancer treatment as a result of improvements 
in our understanding of the biological interaction between cancer cells and the immune system. 
This has led to the successful discovery of checkpoint inhibitor antibodies (checkpoint blockers 
against CTLA4, PD-1, and PD-L1) which activate the adaptive cancer-immune response [49]. 
After FDA approval of two melanoma treatments, Ipilimumab and Vemurafenib, the death rate 
due to melanoma decreased by 7% per year during the years 2013-2017 [51]. Treatment based 
on antibodies has advanced the clinical management of multiple diseases, including cancer. The 
number of therapeutic antibodies approved by the FDA has increased in the last few years [52]. 
Recent studies have demonstrated enhanced effectiveness of immunotherapy when combined 
with radiotherapy through the “abscopal” effect [53] Yilmaz et al, 2019; Eldridge et al, 2020). 




area of metastatic cancer, cancer shrinkage may result in an untreated area as a result of the 
radiation[54]. While this phenomenon was seen as a rare occurrence in the past, it has become 
more frequent with the arrival of immunotherapy drugs such as checkpoint inhibitors [55]. The 
combination of immunotherapy and radiotherapy is one of the new promising strategies to 
minimize the side effects of nonspecific treatment [56]. This modality of treatment is referred to 
as radioimmunotherapy (RIT). 
2.3.6 Radioimmunotherapy (RIT) 
           Targeting of radionuclides with antibodies for cancer treatment and imaging has been an 
active field of research since the discovery of mAbs. It has evolved with advancing technologies 
in molecular biology, radiobiology, and chemistry, and many important preclinical and clinical 
studies illustrate the benefits [57]. It is a systemic treatment which aims to deliver cytotoxic 
radiation specifically to cancer cells while minimizing the radiation exposure to healthy tissue 
[58]. The system utilizes monoclonal antibodies or its fragments as carriers which bind specific 
antigens on the surface of cancer cells (Figure 2). Radionuclides emit ionizing radiation, which 
can be utilized as endoradiotherapy for ionization and free radical formation [59]. This causes 
significant damage to cellular structures and organelles, including the nucleus and the DNA [60]. 
Currently, there are some radiolabeled antibodies approved for treatment of non-Hodgkin’s 
lymphoma “90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar)” [61], both of 
which are anti-CD20 monoclonal antibodies coupled with cytotoxic radioisotopes. Also, 177Lu-
DOTATATE was approved for gastroenteropancreatic use in 2018 [62]. While 
radioimmunotherapy was quite successful for hematological malignancies, treating solid tumors 
remains a challenge [63] as a result of poor tumor penetration of the antibodies and its 




With all the different antibody forms made possible through molecular antibody 
engineering, it is important to keep in mind that radionuclide selection may vary based on the 
antibody’s biodistribution, tumor retention, and blood clearance properties [65]. Also, the type of 
chelator and conjugation processes may affect antibody binding and radionuclide selection [66]. 
Even after radiolabeling, stability and retention of binding must be carefully tested [67]. 
Therefore, a number of factors including physical and chemical properties contribute to the 
selection of the most appropriate radionuclide for a radioimmunoconjugate [68]. While there are 
many radionuclides from which to choose, availability and cost have limited the choices for 
clinical use.  
 





2.4 Radiolabeling Strategy 
 
The radiolabeling strategy is to attach a particular radionuclide to a mAb, an antibody 
fragment, or a minibody. It is dependent on the type of radionuclide, (e.g. halogen versus metal), 




There are many radionuclides which have been used successfully for clinical therapy 
such as iodine-131 (131I), phosphorous-32 [32P], strontium-90 [90Sr], and yttrium-90 [90Y]. 
Table 1 shows a list of therapeutic radionuclides that have been used either in clinical or research 
settings. A number of factors are considered when selecting appropriate radionuclides [68]. Such 
factors include the radionuclide’s physical properties, such as the radionuclide half-life, energy 
and intensity of radiation emitted, and emission characteristics, chemical properties, production 
methods, and biological behavior such as dissociation from the carrier [68]. In addition, cost, 
availability, and linkage chemistry play a role in choosing radionuclides for labeling the 
antibody. Radionuclides can be classified as either diagnostic or therapeutic based on the 
emission the radionuclide produces. Radionuclides typically used for therapy produce beta 
particles, alpha particles, Auger electrons, or isomeric transition [70]. Some radionuclides can 
emit these energy particles together in different ratios [71]. These emissions can irradiate tissue 
volumes with multicellular, cellular, and subcellular dimensions. Radionuclide action is 




per unit path length and is termed liner energy transfer LET. Radionuclides differ in their LET 
due to type of decay [72] (Figure 4). Therapeutic radionuclides vary in penetrating range and 
LET, and again depend on the type of decay. Some decay in the form of alpha (α )- or beta- 
particles (β ), or Auger electrons (AEs) and electron magnetic radiation in the form of X-ray or 
γ ray [71]. Additionally, some radionuclides emit positrons or γ rays. Therefore, they are useful 
for imaging using positron emission tomography (PET) (e.g.15O, 13N, 11C,18F,89Zr, 64Cu and 
52Mn) or single-photon emission computed tomography (SPECT) (e.g.123I and 99mTc and 111In) 
 
[70]. Furthermore, theranostic radionuclides are radionuclides which emit both particulate (e.g. 
beta or alpha particles) radiation as well as electromagnetic radiation , (e.g. gamma-rays) for 
therapy and imaging (diagnosis) respectively such as 67Cu, 67Ga, 99mTc, 177Lu, 111In, 123I, and 
111At [70]. 









β−-emitters (LET: 0.2 keV/μm) 
90Y 2.67 d 2280.0 11,300 β− 
131I 8.02 d 606.31 2300 β−, ɣ 
177Lu 6.65 d 498.3 1800 β−, ɣ 
67Cu 61.83 h 577.0 2100 β−, ɣ 
186Re 3.72 d 1069.5 4800 β−, ɣ 
188Re 17.01 h 2120.4 10,400 β−, ɣ 
Auger emitters (LET: 4–26 keV/μm) 
111In 2.80 d 26 17 Auger, ɣ 
67Ga 3.26 d 9.6 3 Auger, β−, ɣ 
195mPt 4.02 d 64 76 Auger 
125I 59.41 d 31.7 20 Auger, ɣ 
α-emitters (LET: 50–230 keV/μm) 
213Bi 45.59 min 8400 90 α, β−, ɣ 
212Bi 60.54 min 7800 100 α, β−, ɣ 
211At 7.21 h 7500 80 α, EC 
212Pba 10.64 h 7800 100 α, β−, ɣ 
225Ac 9.92 d 8400 90 α, β−, ɣ 





2.4.1.1 Alpha-Emitting Radionuclides (α-decay) 
 
Some unstable atomic nuclei dissipate excess energy by emitting an alpha particle 
(helium nucleus) because alpha particles have two positive charges and a mass of four units. The 
emission from nuclei produces daughter nuclei having a positive nuclear charge or atomic 
number two units less than their parents and a mass of four units less (Scheme 1).  
Alpha-emitting radionuclides are a promising type of radiotherapeutics which show great 
potential in the treatment of a broad range of malignancies [74]. Alpha particles have high 
kinetic energy (5-8 MeV) and their range in tissue is about 40-80 µm. An Alpha particle is an 
helium atom and its nucleus consists of two protons and two neutrons [75]. Alpha particles have 
a high linear energy transfer (LET) value of 50-230 keV/µm [76] (Figure 4). As a consequence 
of their high LET, they have greater relative biological effectiveness (RBE) and require less 
radiation per cell kill than beta particles or x-rays [77]. The path length of alpha-particles is 
short, so the energy deposited is limited to a few cells. Thus, they are capable of destroying 
tumors while causing very limited damage to the surrounding healthy tissue [78]. These 
properties seem to be ideal for treating small cells, such as in micro-metastatic cancer [74]. 
Alpha-emitting radionuclides offer the exciting prospect of matching the cell-specific nature of 




a similar range of action [74]. However, for alpha therapy to be effective, the radionuclide decay 
needs to take place at close proximity to the cell or inside the cell. This is dictated by the quality 
of the site specific targeting molecule, such mAb [79]. 
 
Scheme 1 Alpha decay 
2.4.1.2 Beta-Emitting Radionuclides (Negative Beta decay (β- -decay))  
 
Negative beta particles are emitted when the nucleus of radioisotopes have an excess 
number of neutrons. The neutron will convert to proton and emit beta particles which are an 
energetic electron (of relatively small mass) and an antineutrino which has no rest mass nor 
electric charge and does not interact readily with matter (Scheme 2). Therefore, the atomic 
number of this nucleus will increase by one and the mass number will remain the same. These 
are negative beta particles or negatively charged electrons emitted from the nucleus and their 
energy in tissue varies from zero up to maximum [60].  
About one-third of the maximum energy is equal to the average energy of β− particles 
energy [68]. β− particles energy ranges from 0.05 to 2.3 MeV, and they have low LET of about 
0.2 keV/µm with a long penetrating range in tissue (1 mm to several mm) [80] (Figure 4). This 
causes limited ionization and DNA damage involving single-or double-strand DNA breaks, base 
chemical modifications, and protein crosslinks [80]. Consequently, disregarding other 
parameters, such as tumor penetration profiles of radionuclide carriers, higher radionuclide 
concentrations of beta emitters than alpha emitters are required for comparable cell kill.  
β− particles emitters such as 177Lu, 90Y and 131I have been used in cancer treatment [81]. 
However, the long beta particles’ path that crosses multiple individual cells might cause a 




cells are more sensitive to radiation when they are arrested in the G2 phase and are in a good 
oxygenated state (35). The presence of oxygen upon beta particle irradiation generates free 
radical species that are particularly harmful to the nuclear DNA. Both the rate of beta particle 
disintegration (half-life) and amount of radioactivity at the target site influence the killing 
efficacy by competing against the enzymatic repair of the irradiated DNA strands. 
 
n → p + e- + v-e 
 
Scheme 2 Negative beta decay 
2.4.1.3 Beta-Emitting Radionuclides (β+-decay) (Positron emission) 
 
When some of the unstable radioisotopes nucleus have an excess number of protons, these 
protons will convert into neutrons in order to stabilize the nucleus [82] (Figure 3). A proton in the 
parent nucleus decays into a neutron that remains in the daughter nucleus, and the nucleus emits a 
neutrino and a positron. The neutrino has no electric charge nor rest mass, while the positron is a 
positive particle like an ordinary electron in mass but of positive charge. Therefore, positive beta 
decay produces a daughter nucleus, and in each decaying nucleus emits a positron and a neutrino, 
reducing its atomic number by one while the mass number stays the same. The positron does not 
exist for a long period of time in the presence of matter. It will travel a short distance before 
colliding with an electron of a nearby atom, with which it undergoes annihilation. This annihilation 
will emit electromagnetic energy in the form of two 511-keV gamma rays that are emitted in almost 
opposite directions [82] (Figure 3). These are useful photons for imaging because they easily escape 
from the human body and can be recorded by external detectors. When two opposite gamma-rays 




coincidence lines offer a unique detection scheme for forming tomographic images with PET. Many 
radioisotopes decay by positron, such as underging this decay and thereby emit positrons including 
carbon-11, nitrogen-13, oxygen-15, fluorine-18, copper-64, gallium-68, bromine-78, rubidium-82, 
yttrium-86, zirconium-89, yttrium-90,[3] sodium-22, aluminium-26, potassium-40, strontium-83. 
p → n + β+/e + ve 
 
Scheme 3 Positive beta decay 
 
Figure 3. Schematic illustration of an annihilation reaction in tissues. A positron emitted from the 
nucleus and then annihilates with an electron to produce two gamma rays in opposite direction. 










2.4.1.4 Electron Capture (Inverse Beta Decay) 
 
             In this process, a proton-rich unstable nucleus similar to positive beta decay. However, it 
reduces its nuclear charge to one unit by absorbing an atomic electron to convert the proton to a 
neutron and a neutrino. The proton captures an electron from the K or L shell. This process reduces 
the atomic number by one and emits gamma radiation or an x-ray and auger electrons. When the 
electron is absorbed from the electron orbit, the outer orbital electron will fill the vacancy. This will 
set off a cascade of electron transitions with their associated characteristic x-rays emission. The 
transition of losing the outer orbital electron, will result in releasing of energy. When this energy 
transferred to another electron, the electron will be ejected from the atom and this electron is called 
an Auger electron [84].              
   p + e --> n + ν. 
 
Scheme 4 Electron capture decay  
2.4.1.5 Auger-Emitting Radionuclides 
 
Auger electrons are low energy atomic orbital electrons emitted following electron 
capture (EC) decay [79]. They have short ranges of 1-2µm and a high LET. However, they need 
to be internalized into the cell nucleus to be most effective [79]. If internalized, their high LET 
means they can be profoundly cytotoxic. Recent work to improve Auger therapy has led to the 
development of fusion proteins incorporating a nuclear localization sequence (NLS) [70]. The 
LET of Auger electrons range between 4 and 26 keV/μm (figure 4). This high energy produces 
clustered damage in DNA and the cell membrane [84]. Also, many of AE-emitting 




and transfer in several millimeters [84].There are many Auger-emitting radionuclides which 
have been used in nuclear medicine (e.g. 99mTc, 123I, 111In) [74]. 
 
Figure 4. Illustration of the track of α-particles, β-particles or Auger electrons emitted by 
radiolabeled monoclonal antibodies targeted to cancer cells. The short track length of α-particles 
(28–100 μm) and Auger electrons (<0.5 μm) results in high linear energy transfer (LET) values 
of 50–230 keV/μm and 4 to 26 keV/μm, respectively. β-particles have a track length of 2–10 mm 
resulting in LET of 0.1–1.0 keV/μm. The high LET of α- particles (50–100 μm) and Auger 
electrons make these forms of radiation more powerful for killing cancer cells than β-

















2.4.1.6 Gamma (γ) Decay 
 
         This is an electromagnetic radiation usually followed alpha and beta decays. When the 
radioactive nucleus emits alpha or beta particles, the new daughter nucleus left is in an excited state 
and will release energy to allow the proton or neutron to relax back down to ground state. During 
this transition from a high to a low energy state gamma photon is emitted. Gamma rays are photons, 
or packets of high electromagnetic energy of extremely short wavelength. The energy of gamma 
rays ranges from a few keV to ~8 MeV, corresponding to the typical energy levels in nuclei with 
reasonably long lifetimes. This type of decay does not change the structure or composition of 
the atom. It only changes the energy because it does not carry any charge or associated mass. 
Gamma decay includes two other electromagnetic processes, internal conversion and internal pair 
production. In internal conversation, it always accompanies the predominant process of gamma 
emission to some extent. This takes place when the excess energy in a nucleus is directly transferred 
to one of its own orbiting electrons and, as a result, the electron is ejected from the atom. Internal 
pair production happens when the excess energy is directly converted within the electromagnetic 
field of a nucleus into an electron and a positron (positively charged electron) that are emitted 
together. Gamma radiation is emitted by many natural radioisotopes and is also produced artificially 
in fission in nuclear reactors, high energy physics experiments, nuclear explosions, and accidents.  
Although gamma rays are harmful due to the fact that they are generally very high energy and, 
therefore, penetrate matter very easily, it is useful radiation for medical and other purposes. Gamma 
rays have been used in medicine (radiotherapy and diagnosis), industry (sterilization and 
disinfection) and the nuclear industry. Gamma rays produce photons indirectly through gamma-ray 
photon-electron interactions as the gamma radiation travels through a transparent medium. These 
photons are useful for imaging used by both single photon emission computed tomography (SPECT) 






Due to the affinity, specificity, and selectivity, antibodies and antibody fragments, 
including minibodies, make attractive vehicles for delivery of radionuclides  to tumors for 
imaging and therapy [85]. Monoclonal antibodies are macromolecules and, therefore, have 
longer biological half-life because of their size. This enables them to match and label long 
radioactive decay half-life radionuclides [86]. 
Monoclonal antibodies (mAbs) are about (150 kDa) (Figure 1), while antibodies 
fragments <150 kDa (e.g VH or VL domains (15 kDa), scFv (30 kDa), Fab (50 kDa) and Fab’2 
(110 kDa (as shown in Figure 5) [85]. Large size antibodies have a longer circulation time than 
smaller fragments [85]. Monoclonal antibodies are complex molecules comprised of two 
identical light chains and two identical heavy chains held together by disulfide bonds. 
Consequently, they form a Y-shaped molecule containing two identical antigen-binding arms 
(Fabs) and a glycosylated stem region (Fc) separated by a flexible hinge region (Figure 5). The 
Fc region is responsible for the recruitment of cytotoxic effector mechanisms, including the 
activation of a complement cascade and interactions with Fc-receptors on immune cells [85]. The 
Fc also furnishes mAbs with an unusually long serum half-life of several days or weeks through 
interactions with neonatal Fc receptors [86]. Atypical antibodies consist of about 80% of lysin 
residuse [87].The advanced technology in antibody engineering has led to producing humanized 
mAb and its fragments and has improved the conjugation, tumor penetration, and targeting 
affinity [87]. The use of mAbs is well established and currently more than 150 of them are in 
clinical development [52]. In this project monoclonal SAS1B antibodies were used for 







Figure 5. Monoclonal antibody and antibody fragments. Left: Y-shaped structure of antibody. The 
Fc domain consists of the constant part of the two heavy chains, while the Fab domain consists of 
the variable part of the heavy chain and the light chain. Right: Native and engineered antibody 
fragments. Adapted from reference [88]. 
 
 
2.6 Radiochemistry of Radiolabeled Antibodies 
 
Radiolabeling of antibodies can be done either directly or indirectly. While halogen- 
based radionuclides can be used to directly label antibodies, metal-based radionuclides require a 
linker (chelator) molecule to conjugate to the antibody [89]. For example, iodine radionuclides 
are used to either directly label antibodies by electrophilic substitution or indirectly via a 
conjugation group (Figure 6-A). Most other radionuclides label antibodies indirectly via prostatic 










Metal radionuclides, such as zirconium-89, Indium-111, and lutetium-177, require a 
chelator molecule to label monoclonal antibodies indirectly [89]. There are a wide range of 
bifunctional chelators. BFCs have been developed for conjugation of targeting constructs with 
several radionuclides. It is important that BFC produce a large, expedient, and stable yield in 
radiolabeling [91]. The selection of which radiochemical method to use to prepare 
radioimmunoconjugates is based on the physiochemical properties of the radionuclide [89]. For 
instance, the short half-life of some radionuclides does not allow for lengthy reaction conditions, 
and additional purification steps are unfavorable. Due to the diverse properties and coordination 
chemistry of radionuclides, it is difficult to design a chelating agent which can bind to all 
radionuclides. Moreover, selection of BFCs is largely determined by chemical properties, such as 
oxidation state and coordination chemistry [91], and the resulting radiopharmaceutical must have 
high solution stability. Therefore, BFCs must form a metal chelate with high thermodynamic 
stability and kinetic inertness in vitro and in vivo to avoid both accumulation of radioactivity in 




been developed for stability of frequently based radionuclide complexation. There are different 
approaches to conjugating chelator to antibodies. The functional group of the chelator could be 
an aromatic isocyanate or an activated ester, which will react with nucleophilic sites (-NH2,-SH, 
or –OH) of antibody [92]. For example, p-SCN-Bn- DOTA c(S-2-(4-Isothiocyanatobenzyl)- 
1,4,7,10-tetraazacyclododecane tetra acetic acid ), a chelator with isothiocyanate, reacts with the 
N-terminal amino group of the antibody, additional lysine resides, and even arginine residues 
[93]. On the other hand, when it reacts with metal ions of radionuclide, DOTA makes a complex 
structure by coordinating the nitrogen atom of the cyclen ring and carboxy groups of the acetate 
arms [93]. It is useful to know the sites of crosslinking, as well as the amino acid residues in 
monoclonal antibodies which bind to the functional group in chelator when choosing the 
appropriate chelator with specific functional group. This can help avoid undesirable binding of 
chelator with the antibody, such as binding to Fab regions which may lead to nonspecific binding 
inside the body [91]. It is necessary to ensure that the conjugation of a chelator to the antibody 
does not lower the antibody-receptor binding. When the active sequence that confers binding 
affinity is known, the conjugation can be directed. Moreover, conjugation efficiency depends on 






















 3.1 Molecular Imaging 
Molecular imaging is an attractive approach that enables noninvasive visualization, 
characterization, and quantification of biological processes (events) taking place at the cellular 
and subcellular levels in humans and other living systems. Molecular imaging contributes in 
clinical diagnosis, staging of the disease, treatment, and surgery plan [94]. Molecular imaging 
can also provide quantitative information which plays an important role in monitoring cancer 
status over time or in treatment [95]. There are several techniques that are well established 
imaging modalities. These include techniques based on radiation, optical, nuclear magnetic 
resonance, and ultrasound properties (Table 2). MRI and computed tomography (CT) depend 
solely on energy-tissue interactions, whereas others such as PET or optical imaging require the 
administration of radionuclides or optical probes [95]. Positron emission tomography (PET) and 
single-photon emission computed tomography (SPECT) are of great interest from the view of 
high sensitivity as nuclear medical imaging, distribution, and kinetics of a radiolabeled molecular 
probe in which a radioactive molecular probe is administered into the body [96]. The other 
attractive methodology is optical molecular imaging which depends on light photons at different 
wavelengths from visible and infrared ranges resulting from fluorescent and bioluminescent 
events. For instance, using fluorescent probes that can be detected by using a fluorescent imaging 
instrument to study distribution and kinetics. This technique does not involve exposure to 
ionizing irradiation and provides real-time imaging with high spatial resolution inexpensively 
[97],[98]. The most common imaging techniques and their important characteristics and 
applications are listed in table 2. Each of these imaging tools brings its own advantages and 
disadvantages. In order to obtain optimal performance, in most cases the suggestion is to use 




PET/MR [99],[100]. Most image modalities depend on identifying the imaging target and 
selecting an appropriate imaging contrast agent or ligand. Based on specific properties, imaging 
targets can range from cell surface markers or genes and their related products to a particular 
cellular or pathological process [96]. Usually the agent is in the form of a small molecule, 
protein, or antibody that can bind to or enter the target environment upon injection into the 
subject body [101]. In recent years, multimodality probes have been increasingly common for 
improvements in efficiency. 
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3.1.2 Positron Emission Tomography (PET) 
 
Positron Emission Tomography (PET) is widely used as a molecular imaging approach 
for research and clinical needs using different radionuclides Table 3. PET is a minimally 
invasive imaging procedure with a wideranges of clinical and research applications. PET allows 
for the three-dimensional mapping of administered positron-emitting radiopharmaceuticals such 
as 18F-fluorodeoxyglucose (for imaging glucose metabolism). Also, PET enables the study of 
biologic function in both health and disease. In addition molecular imaging with PET allow the 
visualization of various molecular pathways including metabolism, prolife-elation, oxygen 
delivery and consumption, and receptor or gene expression, all of which may be important in the 
response to ionizing radiation[102]. Furthermore, PET can be used to evaluate novel 
radiolabeled PET imaging agents, effectiveness of new therapies, and biodistribution of novel 
pharmaceuticals in suitable animal models. 
PET is based on using the advantage of the unique properties of radioactive isotopes that 
decay via positron emission. The nucleus of these radioisotopes has an excess of protons and, in 
order to reach stability, protons transform into a neutron, a positron, and a neutrino. The newly 
formed short-lived positron is ejected from the nucleus and interacts with an electron from the 
surrounding environment after traveling a distance. This is called positron annihilation, resulting 
in the emission of two 511 keV gamma rays traveling in opposite directions (Figure 7 and 8). 
Image acquisition is then based on simultaneous detection (coincidence detection) of these two 
gamma rays Figure 9. By acquiring a large number of such events, tomographic reconstruction 
methods can be used to reconstruct two dimensional images of the tracer distribution. 




resonance imaging (PET/MRI). The functional metabolic imaging of PET is fused with the 
anatomical structure imaging of CT or MRI, which can obtain information such as function and 
metabolism, and can also have high spatial resolution and accuracy. Moreover, a variety of PET 
radiotracers have been introduced. 
Table 3.Most comomly used PET radionuclides. 
Radinuclide Imaging modality Half-life 
15O PET 2.05 min 
13N PET 9.96 min 
11C PET 20.4 min 
18F PET 109.7 min 
68Ga PET 67.6 min 
64Cu PET 12.7 h 
89Zr PET 78.4 h 
76Br PET 13.1 h 







Figure 7. Small animal positron emission tomography (PET). A: schematic illustrating the basic principles of PET. 
First, a targeted imaging agent (e.g., small molecule, peptide, engineered protein, aptamer, nanoparticle) containing a 







Figure 8. Illustration of an annihilation reaction in tissues and the subsequent coincidence detection 
in PET detector. Adapted from reference [103]. 
 
3.1.2.1 Coincidence Detection 
 
             PET records only true coincidence events that originate as a result of positron annihilation 
along the line between the two parallel opposite detectors (Figure 9-A). These events carry 
information regarding the spatial location of the positron source. The detector pair should ideally 
produce signals simultaneously. In cases of true coincidences, but due to limitations of scintillation 
detector as well as associated electronics, coincidence events are accepted within a finite interval 
which is of the order of 4 to12 ns. Therefore, two unrelated photons may be detected and get 
registered as coincidence events (Figure 9-B).   These events are called random or accidental events 
and they provide useful information regarding spatial location of activity distribution which needs to 
be corrected. These accidental events cause noise and increased background in the final images. In 
addition, sometimes both of the annihilated photons are diverted from their original direction as a 





   
A-True coincidence events             B-Random or accidental events    C-Scattered coincidence events 
 
Figure 9. Types of coincidence events. True coincidence detection occurs when the two gamma rays 
are detected from one annihilation event in the time window. Random coincidence occurs when both 
photons detect in the time window and are from deferent annihilation events. scattered coincidence occur 
when at least one of the gamma photons under goes Compton scattering, and both photons still detected 
in the time window.  
     
3.1.2.2 Production and Applications of PET Radionuclides 
 
Positron sources are produced artificially because they are not stable in nature. They are 
produced by bombarding stable isotopes with positively charged particles. This requires using a 
cyclotron to generate short-lived radionuclides such as 18F (t1/2 = 109.8 min), 64Cu (t1/2 = 12.7 h), 
and 76Br (t1/2 = 16.2 h), or ultra-short-lived radionuclides such as 11C (t1/2 = 20.3 min), 13N (t1/2 = 
10 min), and 15O (t1/2 = 2.04 min) (143). There many radionuclides that have been used for 







Table 4. Example of some radionuclides production. 
 
Radioisotope Half-life (h) Decay mode (%) Application 
F-18 1.8  EC β+(97), (3) 18F-FDG  




























  Usually PET scans are combined with computed tomography (PET/CT) or magnetic 
resonance imaging (PET/MRI). This provides functional metabolic imaging of PET and anatomical 
structure imaging of CT or MRI, so in addition to the information of the function and metabolism, it 
will have high spatial resolution and accuracy. 
Positron Emission Tomography (PET) has emerged as one of the greatest tools used for 
clinical applications (Table 5). FDG PET being better than MRI and CT in detecting lymph node 
metastasis from SSC [104]. Providing metabolic functional imaging and pathologic processes by 
using PET images opened newer options for incorporation of this information into patient 







 Table 5. Commonly used PET tracers for clinical molecular imaging of diseases. Adapted from 
reference [105]. 
Medical Imaging Molecular Target Radiotracer(s) Clinical Applications 
Oncological Imaging Protein synthesis 11C Methionone, Protein synthesis in tumors 
 
Glucose transporter 11C-DG, 18F-FDG Glucose metabolism in tumors 
 
Choline transporter 11C-choline Tumor phospholipid synthesis 
 
thymidine uptake in 
DNA/RNA synthesis 
18F-FLT, 18F-FMAU; 18F-FU Tumor cell proliferation 
 
αVβ3 integrin 18F-galacto-RGD Tumor angiogenesis  
HSV1-tk 18F-FHBG Suicidal gene therapy 
 




Somatostatin receptor 64Cu-TETA-octreotide Neuroendocrine tumors 
 
Estrogen receptor 18F-FES Breast Cancer 
 
Androgen receptor 18F-FDHT Prostate Cancer 
Cardiovascular Imaging Cell metabolism 11C Acetate Cardiac metabolism 
 








18F Norephinephrine Cardiac sympathetic 
innervation 
Neurological Imaging Dopamine post synaptic 
receptors 
11C Raclopride Schizophrenia, Addiction 
 
β-amyloid 11C-PIB Alzheimer’s disease 
 
NK-1 Receptor 18F SPARQ; 11C-R116301 Depression, Anxiety 
 
Dopamine transporter 18F FECNT Schizophrenia, Addiction 
 
Dopamine metabolism 18F DOPA Schizophrenia, Addiction 
 
3.2.2 Single photon emission computed tomography SPECT 
 
Single photon emission computed tomography (SPECT) is a nuclear medicine imaging 
technique using gamma rays. SPECT provides a 3D image to visualize and measure biological 
processes within living systems. The basic principle for SPECT is based on using the advantage 
of nuclides such as 99mTc (t1/2 = 6 h), 123I (t1/2 = 13.3 h), and 111In (t1/2 = 2.8 days), which 




emit gamma-ray inside the body, it can be detected using a single or a set of collimated radiation 
detectors[106].Two or three gamma cameras rotate and detect gamma rays produced by 
radionuclides from different angles. The detectors used in current SPECT systems mostly 
depend on a single or multiple NaI (TI) scintillation detectors [106]. When gamma rays produce 
light photons (415nm) which enter the scintillator and ionize the iodine atoms, these photons are 
converted to an electrical signal which is then recorded and used to reconstruct multiple two- 
dimensional images and generate cross-sectional images [107]. In SPECT, projection data are 
acquired from different views around the animal or patient (Figure 10 &11). Table shows the 
most common used radionuclides and it applications. 
Table 6. Most commonoly used SPECT radionuclides. 
Radioisotope Half-life (h) Decay mode (%) Application 
Tc-99m  
 
6.0 IT(100), γ Used for diagnostic 




78.3 EC(100), γ Imaging 
(SPECT) 
I-123 13.2  EC(100), γ Imaging 








Widely used in clinical 
practice for diagnosis 
Lu-177  
 
















Figure 10. Small animal single photon emission computed tomography (SPECT). A: diagram 
illustrating the principles of SPECT, i.e., a targeted SPECT imaging agent (containing a gamma 
emitting radioisotope) is administered to the subject and the gamma rays are detected via a gamma 
















3.3 Optical Imaging 
 
Optical imaging techniques offer simplistic while highly sensitive modalities for 
molecular imaging research. Non-invasive images help with identification and localization of 
tumor lesions and characterization of processes involved in tumor proliferation and invasion, 
concurring to the description of tumor features, staging, treatment evaluation, and as image-
guided-surgery[108]. 
Images are generated by using photons of light in the wavelength range from ultraviolet 
to near infrared. The contrast of optical images can be derived through using exogenous agents 
such as dyes or probes, or by using endogenous molecules which can provide a signal such as 
NADH, hemoglobin, collagens, and reporter genes [109]. The strategies of optical imaging are 
based on the use of injectable fluorescent or luminescent probes that provide the possibility to 
study tumor features. Currently, most of these probes are used only in animal models, but the 
possibility of applying some of in clinics also is under evaluation [108]. 
3.3.1 Fluorescence molecular imaging (FMI) 
 
Fluorescence molecular imaging (FMI) is emerging as a technology with substantial 
potentials that enable in vivo imaging of molecular and cellular processes with high 
sensitivity[110]. FMI has gained great popularity over the past decade, mainly because of its safe 
and straightforward use. The application of fluorescence molecular imaging would also help 
bioengineering scientists investigate disease processes, evaluate therapy response, and develop 
new drugs. FMI is based on using an engineered imaging of fluorescence agents to target specific 
disease biomarkers. When fluorescence agents are excited with a light source, fluorescence is 
emitted as photons during the return to a ground state of electrons excited by photo-stimulation. 




band-pass filters to block photons at the excitation wavelength and allow the recording of 
photographs of emission (fluorescence) photons exiting the tissue surface. Depending on the 
particular light-sensitive technology employed, there are different operational specifications and 
spectral regions spanning 400–1,700 nm which can be implemented. For example, a charge- 
coupled device (CCD), indium gallium arsenide (InGaAs), or a complementary metal-oxide– 
semiconductor (CMOS). There are also many different fluorescent agents that target 
biochemical and molecular features of diseases that are being approved for experimental clinical 
use. For instance, a folate receptor-targeting fluorescence agent has been used to improve 
detection of ovarian cancer in patients [111]. Also, fluorescently labeled cetuximab has been 
employed to improve precision in oral cancer surgery [112]. Fluorescence molecular imaging 
can obtain high sensitivity detection with low instrumentation expense compared with other 
molecular imaging approaches. 
Moreover, a protease-activated fluorescent agent was also considered in humans for 
detecting soft tissue sarcoma [113]. Additionally, using a targeted heptapeptide for 
detection of colonic dysplasia and detection of Crohn’s disease using a fluorescent labelled 
antibody targeting tumor necrosis factor has been demonstrated in humans [114]. 
Fluorescent molecular imaging can obtain high sensitivity detection with low 
instrumentation expense compared with other molecular imaging approaches.  
            Fluorescent imaging is also used to assist surgeons in delineating malignant from benign 
tissue. The increasing availability of fluorescent proteins, dyes and probes enables the non-invasive 
study of gene expression, protein function, protein-protein interactions and a large number of 
cellular processes [115]. This body of information has great attention for using fluorescent 






3.3.1.1 Near-infrared (NIR) Optical Imaging 
 
High-resolution near-infrared (NIR) optical imaging has become an attractive modality 
for non-invasive visualization of deep tissues. Because of its high tissue permeability, low 
absorption and low scattering of NIR light as well as low auto fluorescence, near-infrared (NIR) 
dyes have received increasing attention in recent years as diagnostic and therapeutic agents in the 
fields of tumor research and clinical applications. They are small organic molecules that function 
in the NIR wavelength region (700–1400 nm). Compared to other modalities such as magnetic 
resonance imaging (MRI), X-ray computer tomography (X-ray CT), and positron emission 
tomography (PET), NIR optical imaging has a high spatiotemporal resolution (∼μm) enough to 
visualize cellular dynamics at the whole-body level. In addition, NIR optical imaging has no 
radiation effect. Molecular imaging can also be achieved easily using NIR optical probes, such as 
antibodies which specifically bind over expressed cancer cell surface antigens. 
3.3.1.2 MULTISPECTRAL IMAGING Multispectral Imaging (MSI) 
 
This is a fluorescence-based optical technique which optimizes the opportunities for 
multiplexing while at the same time overcoming the effects of autofluorescence on detectability 
and reliable quantitation [116]. In this technique, it is possible to acquire multispectral datasets 
by simply rotating a filter wheel in front of a CCD camera. The use of electronically tunable 
filters (no moving parts, continuous tunability) is also attractive. When the multispectral image 
set is captured, spectral unmixing and signal quantitation and display complete the imaging 
process. This system offers a high spatial resolution, good reagent flexibility, high throughput, 
and compatibility with relatively high levels of multiplexing. 
The Maestro™ is one of the multispectral imaging systems (CRi, Woburn, MA, 01801) 




crystal tunable filters which are band-sequential filters and easily coupled to focal plane array 
detectors employing CMOS, standard CCD, or EMCCD technologies, among others. A complete 
image can be acquired by sequentially tuning the filter and exposing the sensor at each wavelength. 
The user can easily vary the exposure time as a function of wavelength. Therefore, this allows the 
ability to optimize signal-to-noise in situations where sensitivity (emitted photons convolved by 
imaging receiver characteristics) varies over the spectral range. Moreover, it is possible to maximize 
signal-to-noise by acquiring only the most informative bands because the wavelengths acquired can 
be arbitrarily spaced through the spectral range of interest. 
3.4 Radio-immuno-Imaging 
 
              Many tumors have either unique or over-expressions of specific receptors that can be 
exploited for both diagnosis and therapy [117]. Currently, there are several approved 
radiopharmaceuticals specifically targeting cancer surface receptors and a major amount of ongoing 
research to develop new receptor-based imaging agents (Figure 7) [118]. Tumor receptor imaging 
provides complementary information which includes evaluation of the entire tumor and 
characterization of the heterogeneity of tumor receptor expression. The most important element for 
tumor receptor targeting is the nature of the ligand-receptor interaction [119]. There are several 
considerations regarding the selection of specific radionuclide, ligand linker, and labels for different 
situations. Notably, the requirement of imaging probe is that it should be low molecular 
concentration to avoid saturating the receptor and increasing the background because of nonspecific 
uptake, and also the metabolic stability in vivo pharmacokinetics, and imaging label 
characterization. The label should remain attached to the ligand so it will not accumulate in normal 
tissue.  The ligand should have high receptor specificity and affinity so that it binds to the desired 
receptor well and does not bind significantly elsewhere. More importantly, the label must have a 




background. Antibodies bind very effectively to specific receptors and have long half-life.  
              One well-known antibody example in binding to a cell receptor is capromab pendetide, 
which binds specifically to the prostate specific membrane antigen (PSMA) [120]. There are many 
receptors highlighted, and recent investigations of receptor imaging with other molecular imaging 
modalities are reviewed. Molecular imaging of tumor receptors has been mainly confined to 
radionuclide imaging (PET and SPECT), with which it is possible to generate images with 
micromolar to picomolar concentrations of imaging probes. In addition, using optical imaging based 
on near-infrared appears promising. 
Table 7. Examples of preclinical RIT studies in solid tumors adapted from reference [71] 
Target antigen Targeting moiety Radionuclide Model 
hK2 Murine Ab 177Lu Prostate cancer 
CD138 mAb 213Bi Ovarian carcinoma 
EGFR mAb 177Lu OSCC 
TROP-2 mAb 177Lu Prostate cancer 
GPA33 mAb 177Lu/86Y Colorectal cancer 
NaPi2b F(ab’)2 211At Ovarian cancer 
PSMA mAb 177Lu Prostate cancer 
HER2 mAb 212/213Bi Colon adenocarcinoma 
HER2 Affibody 177Lu Ovarian carcinoma 
HER2 mAb 212Pb Colon adenocarcinoma 
CD138 mAb 131I Breast carcinoma 
HER2 mAb 227Th Breast carcinoma 
FR F(ab’)2 131I Ovarian cancer 
EGFR mAb 177Lu Epidermoid carcinoma 
MUC1 mAb 177Lu Breast carcinoma 
HER2 mAb 177Lu Breast carcinoma 
PD-L1 mAb 111In Breast carcinoma 
HER2/EGF bsRICs bsRICs 177Lu/111In Breast carcinoma 
EGFR mAb 213Bi Bladder carcinoma 
L1CAM mAb 177Lu Ovarian cancer 
ROBO1 mAb 90Y Small cell lung cancer 
TfR mAb 90Y Pancreatic cancer 
Lewis Y mAb 177Lu Colon carcinoma 
 
In this project SAS1B receptor was the image target using radiolabeled anti-SAS1B as will be 

































4.1 Introduction.   
 
A number of monoclonal antibodies (Anti-SAS1B) have been produced including SB2, SB3, 
SB4, and SB5 and according to UVA studies, most of these antibodies were identical [121].  
Therefore, SB2 and SB5 were selected for labeling with radioisotopes and near infrared dye and 
then investigated in vitro and in vivo studies. Among a number of radioisotopes and based on their 
physical and chemical properties, 89Zr and 67Cu were selected to radiolabel anti-SAS1B antibodies 
for in vivo imaging and ex vivo biodistribution studies.89Zr possess favorable characteristics 
antibody-based for PET imaging [122], [123]. In addition, the production of 89Zr was carried out in-
house at VCU. 67Cu emits gamma radiation which can be used for Single-Photon Emission 
Computed Tomography (SPECT) [124]. Also,67Cu it is one of the best suited isotopes for 
radioimmunotherapy because its half-life is long enough to allow good biodistribution within the 
tumor  [125]. These radionuclides require bifunctional chelators to obtain the best labeling with 
antibodies [126]. Bifunctional chelators are capable of coordinating a metal ion and can also be 
attached to the antibody [127] . Each radionuclide has its favorable chelators which can form a 
complex and reduce detachment of radioisotope [128]. Labeling anti-SAS1B antibodies done 
indirectly through two steps including optimization of antibody to the chelator conjugation and 
labeling with radionuclide to form a complex with the chelator. Labeling antibodies is challenging 
because there are many factors that need to be addressed during conjugation and labeling including 
the optimal ratio between chelator and antibody, reaction solution, pH, temperature and time of the 
reaction [90].   
The other imaging agent used for an optical imaging was near infra-red dye (IR800CW). IR800CW 
dye is one of the main dyes used for fluorescence imaging [129]. Near infra-red dyes provide deep-
tissue and real-time fluorescence imaging [130]. IR800CW linked to NHS-ester group which bind to 




column. Optimizing the molar ratio of dye-to-antibody is important to determine the best ratio of 
anti-SASB1 to dye and used for in vitro and in vivo experiments. Among anti-SAS1B antibodies, 
(SB5) was selected for radiolabeling with 89Zr and (SB2) was labeled with 67Cu and NIRdye 
800CW as described below. 
4.2 Synthesis of Non-radiolabeled and 89Zr Radiolabeled anti-SAS1B (SB5). 
 
   Anti-SAS1B (SB5) was labeled with 89Zr indirectly through DFO-NCS linker (Chelator) 
through two steps. First, SB5-DFO cold conjugation was optimized and then labeled with 89Zr. 89Zr 
readily available from our in- house cyclotron. 89Zr exists as large ion and +4 cation in aqueous 
solution, and can be classified as a hard cation [131], so it exhibits a preference for ligands bearing 
up to six hard, anionic oxygen donors with chelators such as Desferrioxamine B (DFO) [132]. 
Desferrioxamine B was selected for this study because it is currently the best available ligand for 
Zirconium chelation and its use has been demonstrated in a number of preclinical and clinical 
studies [133]. DFO is a bacterial siderophore bearing 3 oxime groups. Computational studies 
strongly suggest that DFO forms a hexacoordinate complex with Zr4+ in which the metal center is 
coordinated to the three neutral and three anionic oxygen donors of the ligand as well as two 
exogenous water ligands as shown in Figure 12. 
 
 





4.2.1 SB5 Conjugation 
 
The conjugation reaction schematic is depicted in scheme 5. Fifty µg of SB5 was added to 
500μl of PBS (phosphate buffered saline solution) and the pH was adjusted to 8.8-9.0 using 0.1M 
sodium bicarbonate.  DFO solution was prepared by weighting 0.2 mg added to 150 µl of DMSO to 
make 1.5 mg/ml solution. From DFO solution, 20μL was taken and added to SB5 mAb solution. 
The mixture was incubated at 37°C and mixed a rotating speed of 300 rpm for 60 minutes.  
 
Scheme 5 Reaction Schematic of DFO to SB5 Conjugation. 
 
 
4.2.1.2 SB5-DFO Characterization. 
 
The conjugation yield of SB5-DFO was monitored using HPLC-UV (High-performance liquid 
chromatography and ultraviolet detector) with size exclusion column (SEC) (Superdex 200 10/300 
column GE Healthcare, Piscataway, NJ USA) at room temperature. 0.01 M phosphate buffer and 
0.14 M NaCl, pH 7.4 were used as mobile phase at flow rate of 0.5 mL min. UV detection was 









4.2.2 Radiolabeling SB5 with 89Zr. 
 
Zirconium-89 was produced in the cyclotron using the 89Y (p, n) 89Zr reaction using 13 MeV 
incident proton energy. Following radiochemical processing, 89Zr was obtained in the form of 
Zirconium-oxalate solution.  [89Zr]-oxalate (4.2 mCi/500uL) solution was neutralized with 200uL of 
2M Na2CO3.  15uL of [89Zr] - oxalate solution was added to SB5-DFO conjugation solution and 
incubated for 30 minutes. Radiolabeling reaction schematic is shown in scheme 6.  
 
Scheme 6 Reaction Schematic of radiolabeling of SB5-DFO with 89Zr ([89Zr]-DFO-SB5). 
 
4.2.2.1 89Zr-DFO-SB5 Characterization 
 
The reaction yield was monitored by radio-HPLC. Radio detector was connected to UV-
HPLC to detect the radio activity signal of labeled antibody. This one of the methods used to 
determine the radiochemical purity of radiolabeled antibodies. Radiochemical species can be 
separated according to the molecular size and weight, and the peak of radiolabeled antibody will 
correspond to the peak in UV-HPLC. The [89Zr]-DFO-SB5 solution (20ul) was loaded on Radio-
HPLC from waters using size exclusion column (SEC) (Superdex 200 10/300 column GE 
Healthcare, Piscataway, NJ USA) and the radio detector was connected to the HPLC is Bioscan, 
INC, model BFC-3300.The mobile phase was 0.1 M phosphate buffer and 0.14 M NaCl2, pH 7.4, at 




4.2.2.1.2 Radio-TLC. Thin-layer Chromatography 
 
The radiolabeled SB5 [89Zr]-DFO-SB5 was also monitored by radio-TLC. Thin-layer 
chromatography was performed on TLC plates (silica gel plates [Sigma-Aldrich,St. Louis, MO]). 
TLC plates at heights 10cm approximately 1ul of the final solution were spotted at the center of the 
2 cm mark from the bottom. The spot was allowed to dry for 5 to 10 minutes. The plates were then 
placed into a TLC jar filled to about 1cm from the bottom with 10% ammonium acetate and 
methanol (1:1) as a mobile phase, and allowed to develop to the 7 cm line from the bottom (about 15 
minutes). In this system radiolabeled antibody remains at the origin, while free [89Zr] migrate to the 
solvent front. Also, Size exclusion column PD10 was used to purify [89Zr]-DFO-SB5. Using this 
column allowed to sort out all labeled antibody from other radioactive components by collecting 
small fractions of the reaction solution and determine the radioactivity using TLC. 
4.2.3 In vitro study of [89Zr]-DFO-SB5 
4.2.3.1 Cell lines and Cell Culture. 
  
SNU539 (Seoul National University) cell lines have been cultured to use them as expressed 
target for in vitro and in vivo study. SNU539 cell lines were established from Korean cancer patients 
since 1982 and reported in many SNU cancer cell lines, SNU539 was characterized and reported in 
uterine tumor tissue (56). SNU539 Cell lines were grown and maintained in RPMI1640 
supplemented with 10% heat inactivated fetal bovine serum (Hyclone,Logan,UT), 2mM L-
glutamine (2mmol/L), 100 ug/ml  streptomycin (Sigma, St. Louis MO). 10 mM HEPES in a 
humidified, 5% CO2 incubator at 37°C. Every other day cells were checked and medium replaced. 
When cells growth covers about 70% of the flask, cells detached using accuatase enzyme. Then, 
cells were collected, counted and regrow again. When the number of cells reached the required 





4.2.3.2 Cell Uptake 
 
SNU539 cells were cultured and different concentrations prepared 4x106, 2x106 and 0.5x106 
for cell uptake of [89Zr]-DFO-SB5. Cells were incubated at 37°C for 2 hours with the same amount 
of radioactivity [89Zr]-DFO-SB5. After 2 hours, all cells were washed using PBS and spun for 5 
minutes at 1000 rpm. After spun all tubes, supernatant was removed and replaced with PBS. The 
radioactivity of participation cell pellets and supernatants were measured using gamma counter. The 
uptake of cell was calculated and presence of radioactivity of cells reflects the binding of 
radiolabeled SB5 to SAS1B antigens on cell surface. 




Animal experiments were performed according to the policies and guidelines of the Animal 
Care and Use Committee (IACUC) at Virginia Commonwealth University. Female nude mice 3 
weeks old, obtained from the National Cancer Institute in Bethesda, MD, were caged in groups of 
five or fewer, and provided with food and water ad libitum. All animal experiments were performed 
for this study in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines 
and approved protocol at Virginia Commonwealth University.  
4.2.4.2 Mouse Tumor Model 
 
SNU539 cells were inoculated subcutaneously into mice flanks to implant xenograft tumors.  
About (5 × 106) of SNU cells in 130ul of phosphate buffer mixed with 30% matrix gel was injected 




about 1mm in diameter and the volume less than 2000mm3 (Tumor volume calculated using this 
formula V= W*2*L/2 [135]) animal were used for in vivo imaging and biodistribution study. 
4.2.4.3 PET/CT Imaging 
 
[89Zr]-immuno-PET is a quantitative technique to measure the uptake of radiolabeled 
antibody in tumor-associated antigens and the distribution in other organs.  A female nude mouse 
was injected via tail vain with 247µCi of [89Zr]-DFO-SB5.  After intervals of 2 hours, 24 hours, and 
72 hours, the mouse was anesthetized by 1% to 2% isoflurane inhalation anesthesia, then positioned 
in PET/CT system and images were obtained. The region-of-interest (ROI) was analyzed with the 
percent injected dose/gram of tissue (%ID/g). The animal was imaged by both PET and CT.  CT 
image provided anatomical background for distribution of the radioactivity. Figure 13 shows in vivo 
experiments flow work. 
 
                                                                                                                                        
Inoculating cancer cells          Xenograft tumor mouse model     Injecting Radiolabeled mAb    PET at 2, 24 and 72  
 
Figure 13.  In vivo flow work. 
 
4.2.4.4   Ex Vivo Biodistribution 
 
The biodistribution of [89Zr]-DFO-SB5 in animals was determined by organ following 
injection and animal sacrifice.  Five nude mice bearing SNU539 tumor xenografts were divided in 
two groups. The first group of 3 mice were injected with a solution of [89Zr]-DFO-SB5. The other 




control) via the tail vein. After 24 hours, one of the mice died.  All other mice were sacrificed, blood 
and tissues were collected from each animal and weighed, and radioactivity of 89Zr in each sample 
was determined by gamma-counting on a Perkin Elmer Wallac Wizard 1470. The radioactivity 
percent of injected dose per gram %ID/g of each organ was calculated using all data, including 
activity of injected solution (Standard), organs weighed and measured activity of each organ. 
The collected organs were blood, heart, lung, liver, gallbladder, spleen, kidney, tumor, femur, and 
muscle. 
4.3   Radiolabeling SB2 with Copper-67 (67Cu) 
 
In addition to Zirconium-89 (89Zr), radiolabeling of SB2 was also investigated using another 
radionuclide, Copper-67 (67Cu). 67Cu is an attractive theranostic radionuclide because its decay 
results in the emission of both therapeutic (beta particles) and imaging (gamma-rays) radiation.  It 
emits beta particles with a mean energy of 141 keV and three gamma rays (91, 93 and 182 keV) 
suitable for SPECT imaging [124]. Additionally, the half-life of 67Cu is 62 h is well suited to the bio 
kinetics of antibodies [136]. Additional advantages to these favorable physical characteristics of 
67Cu are the availability of copper chelators with high in vivo stability [136], [137]. In this study the 
chelator p-SCN-Bn- DOTA (S-2-(4-Isothiocyanatobenzyl)-1, 4, 7, 10-tetraazacyclododecane tetra 
acetic acid) was selected to link 67Cu to SB2. It is an attractive candidate for conjugation of 
radioisotopes to antibodies [138]. In general, macrocycles, like DOTA form complexes that are 
essentially irreversible under physiological conditions and demonstrate higher thermodynamic 
stability than linear chelators, such as DTPA [139] (Figure 14).   
In order to determine the optimum molar ratio of DOTA: SB2, experiments were carried out 





Figure 14. Structure of [67Cu]-DOTA complex adapted from reference [123]. 
 
 
4.3.1 Optimizing SB2-DOTA Conjugation 
 
Determining the molar ratio of chelator binding to antibody is an important factor for 
optimized radiolabeling. Chelators bind to amino acids on the antibody through the functional group 
of the chelator. The p-Isothiocyanatobenzyl DOTA is one of the favored bifunctional chelators for 
labeling antibody with copper radioisotope. It forms hermodynamically very stable complexes with 
copper through the coordination chemistry[123], [136].  DOTA is water-soluble and reacts easily in 
slightly basic solutions (pH 8–9) with lysine side chains which is one of the most common residues 
on antibody surfaces [140].  
 DOTA-SB2 Conjugation was optimized by preparation of multiple molar ratios of SB2-
DOTA conjugation (1:3, 1:5, 1:7 and 1:10) and incubated at 37C for 24 hours. The conjugation 
yield was determined by UV-HPLC using size exclusion column (Phenomenex Yarra SEC 2000 
150x 4.6mm) and mobile phase of 0. 1M Sodium phosphate buffer pH 6.8 with flow rate was 0.35 
ml/min with. The conjugation was monitored for one week at different time points (0, 1, 2, 4, 6, 8, 





4.3.2 Radiolabeling SB2. [67Cu]-DOTA-SB2 
 
Based on the successful optimization of SB2-DOTA conjugation, 67Cu was then used for 
radiolabeling. Cold conjugation of SB2-DOTA at 1:5 ratio was prepared in solution volume of 
200ul of potassium phosphate buffer, and the pH was adjusted between (8 -9) using 0.1M of sodium 
bicarbonate. 10ul (362uCi) of [67CuCl2], in 0.1M HCl (pH=5.0-5.5) was added to SB2-DOTA (pH= 
8-9) solution and the pH was adjusted to about 6- 6.5, using 0.1M HCL. The reaction was incubated 
37°C for 30 minutes. Radiolabeling efficiency and radiochemical purity of [67Cu] -DOTA- SB2 was 
determined by radio-TLC using 10% (w/v) ammonium acetate: methanol (1:1) as the mobile phase. 
In this system, radiometal-labeled antibody [67Cu] -DOTA- SB2 remains at the origin, while DOTA-
[67Cu] or free 67Cu will migrate to the solvent front on ITLC plates. 
4.3.2.1 Purification with PD10 
 
ITLC showed high labeling yield of SB2 antibody [67Cu] -SB2-DOTA and some of [67Cu]-
DOTA-or 67Cu.  In this case, Size exclusion column PD10 was used to purify labeled antibody from 
other species. 
4.3.3 In Vitro Evaluation 
4.3.3.1 Cell Uptake 
 
  SNU539 uterine cancer cell line and SK-OV3 human ovarian cancer cell lines were used for 
study. Both cell lines were grown at 37°C and were maintained until cell count reached about 50 
million.  In triplicate, vials with 1 million cells in 1m of growth medium were prepared, and 100μl 
of [67Cu]-DOTA-SB2 solution was added to each vails. All vials were incubated at 37°C for 4 




pellets were washed three times with PBS. The radioactivity of all samples, cell pellets, supernatant, 
and wash tubes were measured by gamma counter and the uptake for both cell lines was calculated. 
4.3.4 Ex Vivo Evaluation 
 
Animal experiments were performed according to the policies and guidelines of the Animal 
Care and Use Committee (IACUC) at Virginia Commonwealth University. Biodistribution studies 
of both 67CuCl2 and [67Cu] - DOTA were performed ex vivo on 12 female nude mice. After these 
mice were divided into two groups, one group was injected with 67Cu and the other group injected 
with [67Cu] - DOTA. The biodistribution for these two compounds were measured after 1 and 6 
hours as described below. 
4.3.4.1   DOTA-[67Cu] Biodistribution 
  
Six mice were injected via tail with 200ul of [67Cu]-DOTA (2μCi) solution and divided into 
two groups.   Biodistribution was determined in the first group after 1 hour and the other group after 
6 hours (n=3). Therefore, the first group of mice was dissected after 1 hour (n=3), and the second 
group was dissected after 6 hours (n=3).  All organs were collected to measure the radioactivity of 
[67Cu]-DOTA in each tissue by gamma counter. Data showed rapid clearance of [67Cu]-DOTA from 
the kidney after 6 hours while slow in blood, liver, and spleen, (Figure 20). Also, there was no 
uptake of [67Cu]-DOTA by the brain and less uptake in bones and muscles. 
4.3.4.2   67CuCl2 Biodistribution 
 
  Similarly, 67Cu (4uCi) 200ul volume was injected via tail in triplicate mice. The first group 
of mice was dissected after 1 hour and the other group dissected after 6 hours. All organs were 




4.4    Labeling SB2 with NIRdye800CW 
 
NIR dye 800CW is one of the most used dyes for fluorescence image-guided surgery [141].  
It has less interaction with serum proteins and, when injected intravenously, cleared through the 
kidney with some uptake in the liver [142]. The most commonly applied strategy for labeling 
antibodies by using the activated group N-hydroxysuccinimide (NHS)-ester to form covalent bond 
between primary amines of the antibody and carboxylic acid of (NHS)-ester [143] (Figure 15). This 
conjugate to N-terminus of lysine residues which is the most abundancy and accessible amino acids 
in antibodies. As a result, having this could lead to many fluorophores per targeting antibody and 
cause self-quenching, which will reduce brightness and also, when the fluorophores are conjugated 
in or close to the antigen-binding region, could impact the binding capacity [144]. Therefore, 
optimizing the conjugation of antibody with NIR dye 800CW is important to determine the degree 
of labeling that can give high fluorescence signal in vivo with less background. 
                         












4.4.1   Optimizing the Conjugation of Monoclonal Antibody to IRdye800CW 
 
Conjugation of monoclonal antibody SB2 (155 kDa) with NHS-IRDye800CW from LI-COR 
Biosciences (absorption/Emission: 774/789nm) was optimized by following LI-COR conjugation 
protocol. The stock solution was prepared by dissolving 0.1mg dye with 25ul of ultra-pure water 
and mixed thoroughly. The antibody solution was prepared by adding 50ug (0.33nmol) of SB2 to 
125ul of phosphate buffer. The antibody was combined with reconstituted reactive dye at different 
molar ratio 1:1, 1:2, 1:3 and analyzed to determine the optimal conjugation ratio.  IR800CW dye 
was added to SB2 solution and the pH was adjusted between 8.3 - 8.5 using 1M of potassium 
phosphate buffer K2HPO4 , pH 9. The reaction solution was incubated at 20°C -25°C for 2 hours. 
The excess amount of free dye was removed using Zeba desalting column (Thermo Fisher 
Scientific) after equilibrated with 50mM phosphate buffer, pH 8.5.  The conjugation yield was 
determined using UV/Vis systems. 
 
Scheme 7 Labeling SB2 with IR800CW. 
 
4.4.2 In Vitro Evaluation 
4.4.2.1 Cell Culture  
 
SNU539 Cell lines grown in RPMI1640 were supplemented with 10% fetal bovine serum, 
glutamine (2 mmol/L), penicillin (100 unit/ml), HEPES and maintained in a humidified, 5% CO2 




enzyme and collected. Then cells viability checked using trypan blue and counted. All cells 
harvested when reach the number needed for in vitro experiments. 
4.2.2 Cell Binding  
 
Both SNU539 and SK-OV3 express SAS1B, but A549, a lung cancer cell line does not 
express SAS1B. About 0.1x106 of each cell line were grown in 6 plate wells for 24 hours at 37°C. 
After 24 hours cell growth, the media was discarded and cells incubated with SB2 labeled with NIR 
dye 800CW solution at 37°C for 1 hour. Another 6 well plate with the same cells was incubated 
with IgG labeled with NIRdye800CW for 1hour. All cells were washed using phosphate buffer and 
examined by fluoresce microscope. 
 
4.5 Statistical Analysis 
 
The significant differences in the ex vivo and in vivo studies were determined using the equal 
variance analysis (ANOVA) (JMP software), or Student’s t-test. P value of <0.05 was considered as 






































5.1 Radiolabeling SB5 with 89Zr 
5.1.2 SB5 Conjugation   
 
High-performance liquid chromatography (HPLC) results showed high reaction yield of 
DFO–SB5 cold conjugation (Figure 16). The peak of SB5 was at 24 minutes retention time. The 
small peak at retention time 37.12 represent DFO. The area under the peak represents the 
conjugation yield of DFO to SB5. As the HPLC chromatograph show, about 92% of DFO was 
conjugated to SB5. 
 
         
Figure 16. Conjugation of anti-SAS1B (SB5) to DFO (SB5-DFO), 20ul of conjugation reaction was 
injected into HPLC. The chromatogram shows 92% conjugation yield. The retention time of (SB5) 
mAb was 24.1 minutes and DFO retention time was 37.2 minutes. 
5.1.3 SB5 Radiolabeling  
 
5.1.3.1 Radio-HPLC Chromatography 
 
Radio-HPLC was used to determine the radiolabeling yield of SB5 and the radioactive signal 
should match the UV-HPLC SB5 signal if the 87Zr label SB5. The radio-HPLC chromatograph 
showed that the majority 66.96% of radioactive signal matches the UV signal of SB2. There were 
also multiple small peaks which could be SB5 fragments (Figure 17). 
                                  
Figure 17. Radio HPLC shows radiolabeled SB5 ([89Z]-DFO-SB5). Also, it shows also small peaks 








5.1.3.2 Radioactive Instant Thin-layer Chromatography. 
           (Radio-ITLC of [89Zr-DFO-SB5] 
 
The radio-instant thin layer of chromatography showed high radioactive signal of labeled 
SB5 with very small signal representing free 89Zr or [89Zr]-DFO (Figure 18).       
    
Figure 18. Radio-TLC of [89Zr] - DFO-SB5 showing quantitative radiolabeling yield.  
 
5.1.4   In Vitro Study Results 
 
5.1.4.1 Cell Uptake 
 
The radioactivity of participation cell pellet was measured using gamma counter. The 
presence of radioactivity of cells reflects the binding of radiolabeled SB5 to SAS1B antigens on cell 





Figure 19. Radioactivity of different SNU539 cell concentrations after incubated for 2 hours at 37°C 
with Same amount of [89Zr]-DFO-SB5 radioactivity.  
 
5.1.5   In Vivo Imaging of SAS1B Targeting 
 
5.1.5.1 Tumor Growth Monitoring 
 
After injecting 5x106 of SNU539 cells subcutaneous into mice flank to implement the 
xenograft tumor, the mice were monitored for tumor growth. At week 4, the tumors started 
appearing and a clipper was used to take measurements of the length and width of the tumors.         
In most of the mice, tumor size took about 6-8 weeks to reach 1mm in diameter (Figure 20).  
 
 




5.5.2   PET/CT Imaging 
 
  The animal was imaged by both PET and CT.  The CT image provided anatomical 
background for distribution of the radioactivity (Figures 21 and 22).  As the image showed, the vast 
majority of radioactivity is following clearing from the blood, spleen, and liver, as well as other 
organs. The second observation is the right flank of the tumor showing uptake, while the left flank 
did not show any uptake.  This uptake is because of SAS1B binding Labeled SB5.  Also, more 
activity was noticed in the bone and this is more likely due to the detachment of 89Zr from DFO and 
uptake by the bone. 
 
Figure 21. Whole female nude mouse bearing xenograft tumor injected with [89Zr]-DFO-SB5 and 
imaged via PET/CT show the Maximum Intensity Projection 72 hours post injection. Low 








Figure 22. PET /CT coronal and sagittal images, across tumor area, taken at 2 hours, 24 hours, and 
72 hours post inj. Region of interest (ROI) results showed average of less than 1% of activity shown 
in the tumor while more uptake in bone, spleen, and liver. 
 5.1.5.3   Ex Vivo Biodistribution 
 
After 24 hours, biodistribution results showed that about 6% of radioactivity is in the blood 
and the major distribution is in the liver, spleen, and kidney (Figure 25). Also, an interesting 
observation is the non-specific antibody 3A4 (negative control antibody) is showing significantly 
lower uptake, although the specific antibody SB5 did not show significant tumor uptake (less 1%). 
Even though both antibodies were chelated by DFO, results showed more 89Zr detachment from 







Figure 23. Ex vivo results of [89Zr]-DFO-SB5 and [89Zr]-DFO-3A4 biodistribution in two groups of 
mice after 24 hours. Data shows an average of less than 1% tumor uptake in mice injected with 
[89Zr]-DFO-SB5 (Green) while high uptake in blood, liver, and spleen compared to kidney. 
Nonspecific labeled antibody [89Zr]-DFO-3A4 (blue) showed very less uptake by tumor, and similar 
or less uptake in heart, lungs, kidneys, and blood. 
 
5.1.6   Discussion 
 
Cold conjugation of anti-SAS1B (SB5) with the chelator DFO was performed before 
labeling with 89Zr according to published protocol [145]. The results showed greater than 90% of 
conjugation yield in most of SB5 and DFO conjugation. HPLC with size exclusion column was used 
to evaluate the cold conjugation yield [146] [147]. Firstly, anti-SAS1B and the chelator separately 
were injected into the HPLC to identify the retention time of each one, based on their molecular 
weight. Since antibody has higher molecular weight than the chelator, antibody retention time was 
24 minutes, which is less than the retention time of the chelator DFO was at 37 minutes as shown in 
Figure 7. When the cold conjugation injected, the HPLC chromatograph showed two peaks. The 
area under the peaks represents the amount of antibody and the chelator in the conjugation reaction. 
Therefore, HPLC was used for quantitatively monitor the conjugation yield. If complete conjugation 
is achieved, we will see only one peak at the retention time of antibody. However, when both the 




reaction did not go to completion and the area under the peaks reflects the degree of conjugation 
efficiency. 
Once reaction parameters are optimized and validated by radio-HPLC, a second 
chromatographic method was used, namely radio-TLC. This offers a simple and quick method based 
on the migration of radiolabeled antibody versus the migration of non-antibody radioactivity on the 
TLC plate. This method was adopted for rapid evaluation once being validated by radio-HPLC. On 
the radio-TLC plate, the radiolabeled antibody will stay at the origin while non-antibody radioactive 
species will migrate to solvent front. This is done by scanning the entire plate using a faster 
radiation detection. Labeled SB5 [89Zr] –DFO-SB5 was evaluated using thin layer chromatograph 
TLC and the chromatograph showed about 80% of SB5 was labeled with 89Zr. Following the 
successful radiolabeling of SB5 and SB2 with different yields, the radiolabeled antibody needs to be 
purified from any non-antibody radioactivity. This has been accomplished by using PD10 desalting 
columns containing sephadex G-25 resin for rapid buffer exchange, desalting, and removal of small 
contaminants, including salts and radioactive labels. In this system, radiolabeled antibodies elute in 
the first few eluted fractions, while non-antibody radioactivity elutes in later fractions. Collected 
fractions are re-analyzed to confirm purity. 
Purified [89Zr]-DFO-SB5 was used for in vitro and in vivo experiments. Cell uptake study 
using radiolabeled [89Zr]-DFO-SB5 and SNU539 cells showed that the amount of radiolabeled 
antibody taken up by the cells increases with increasing cell concentration. The level of radioactivity 
used ranged from micro curies for in vitro experiments to mille-curie levels for ex vivo and in vivo 
work [148]. For example, longitudinal imaging of the same animal and prolonged biodistribution 
studies usually require larger amounts of radioactivity to be injected in order to detect it days and 
weeks later, depending on the half-life of the radionuclides[149]. Moreover, one also needs to 




materials encountered by the radioactivity [150]. In addition, the amount of radioactivity used need 
not be so high as to cause an effect on the antibody itself [151]. This is why the immunoreactive 
fraction of the antibody needs to be determined at different levels of radioactivity.  Retention of 
immunoreactivity is also desirable following radiolabeling, as a low immunoreactive fraction could 
compromise binding of the antibody to its target protein SAS1B.  
PET/CT images of [89Zr]-DFO-SB5 uptake in general reflect the biodistribution profile, 
including some uptake in tumor (Figures 21 and 22).  The bone uptake is indicative of 89Zr 
detaching from the radio-conjugate and accumulating in bone.  This observation has been reported 
in other studies [152] [153] [154]. The overall biodistribution of [89Zr]-DFO-SB5 (specific for 
SAS1B) and [89Zr]-DFO-3A4 (presumed to be non-specific for SAS1B) is similar across a number 
of tissues including blood. The SNU tumor uptake was slightly higher for [89Zr]-DFO-SB5 than that 
for [89Zr]-DFO-3A4, although the significance of this difference was not determined.  It has been 
shown by western blot that SNU cells express more SAS1B antigen on their surface compared to 
3A4 SAS1B expression level [155].  It is also worth noting that the uptake of [89Zr]-DFO-3A4 is 2-3 









5.2 Radiolabeling SB2 with Copper-67 (67Cu) 
5.2.1 Optimizing SB2 & DOTA Conjugation 
 
The choreographs of HPLC for the different ratios SB2-DOTA conjugation showed the 
highest yield of conjugation for both ratios 1:3 and 1:5, which were >95%% after 24 hours (Figure 
24). HPLC chromatograph (Figure 25) shows SB2-DOTA peaks at the beginning of the reaction 
(Figure 25A) and after 24 hours (Figure 25B).   Chromatograph shows the peak of DOTA is 
completely disappeared and the area under the peak of SB2 was increased, illustrating the complete 
conjugation of DOTA to SB2. 
 
 
Figure 24.  Optimizing SB2& DOTA conjugation, different ratio SB2 & DOTA (1:3, 1:5, 1:10) 
Conjugation yield was measured at 0,2,4,6,8,10 and 12 hour time points during 24 hours by 20ul 







            A                                                                      B 
 
Figure 25.HPLC profile of SB2-DOTA conjugation ratio 1:5. 20ul of SB2-DOTA conjugation 
solution was injected into HPLC. (A) HPLC profile after 30 minutes of reaction. (B) HPLC profile 
after 24 hours of reaction. Almost 100 % of DOTA was conjugated to SB2 monoclonal antibody 




 Conjugation of SB2 with DOTA was stored at 4°C and monitored for one week. The results 














Stability of SB2-DOTA Conugation
1:03 1:05 1:10
 
Figure 26 .Stability of SB2-DOTA was monitored for one week using HPLC. At each time point 
20ul of SB2-DOTA solution was injected into the HPLC. The HPLC chromatogram showed SB2-




5.2.2   Radiolabeling 
 
Radio-TLC results showed >85% radiolabeling efficiency (Figure 27). Also, there is a small 
peak which represents free 67Cu or DOTA-[67Cu] or both together. Therefore, this is required 
purification. 
 
Figure 27. TLC result of [67Cu] –DOTA-SB2. 1μl of [67Cu] –DOTA-SB2 solution was spotted in 
TLC plates and scanned by gamma counter with the appropriate energy window to detect the 




5.2.2.1   Purification with PD10. 
 
          PD10 was used to purify labeled antibody from other species. Figure 28 shows the 
purification result which was greater than 95% of [67Cu] -DOTA-SSB2. 
 




5.2.3   In vitro Evaluation 
 
 5.2.3.1 Cell Uptake 
 
Results showed significant uptake of [67Cu]-DOTA-SB2 by both SNU539 and SK-OV3 cell 
lines p < 0.05, while low uptake of [67Cu]-DOTA and free 67Cu (without antibody). The same 
radioactivity was used (4uCi) and all cell were washed very well using PBS.  The result of 
radioactivity level associated with the cells confirmed specific binding of labeled SB2 to SAS1B 




Figure 29. Results showed that labeled antiSAS1B (SB2) significantly targeted uterine cell lines 
SNU539 and ovarian cell lines SK-OV3 compared with [67Cu]-DOTA or free [67Cu]. SK-OV3 
ovarian cell lines also express SAS1B antigens (24). Further experimentation is required to compare 
the uptake of SNU539 with different cell lines that do not express SAS1B. 
5.2.3.1   DOTA-[67Cu] Biodistribution  
 
Biodistribution of radioactivity data in each organ was collected with high radioactivity after 
one hour in kidney, spleen, liver, and lung.  It also showed rapid clearance of [67Cu]-DOTA from 
kidney after 6 hours while slow in blood, liver, and spleen (Figure 30).  There was no uptake of 






Figure 30. Gamma counter results show the uptake of [67Cu]-DOTA in different body organs after  
1 hour and 6 hours.   
5.2.3.2   Copper 67 (67CuCl2) Biodistribution 
 
As seen in results of 67CuCl2 Biodistribution shown in Figure 31, most of the 67Cu activity 
was cleared by kidney after 6 hours and the activity in urine sample supports that too. Also, almost 
no uptake by the brain and less uptake in the bone. Liver, heart, and blood still showing activity 
after 6 hours. This indicates that some of the 67Cu might bind to some of blood proteins and is still 






Figure 31. In vivo Copper67 (67CuCl2) Biodistribution.  Results showed rapid clearance of 67CuCl2 
from kidney, lung, spleen and urine after 6 hours, while still more uptake in blood, heart and liver 
after 6 hours compared to 1hour uptake.  
 
5.2.4 Discussion  
         
Optimization of antibody to chelator was performed first for SB2 with DOTA to maximize 
conjugation yield and radiolabeling to obtain high radiochemical yield [156] [157].   For SB2-
DOTA conjugation, two parameters were studied, the molar ratio of mAb to chelator/linker and the 
time of conjugation reaction. Three different ratios, 1:3, 1:5, and 1:10, were investigated for 
conjugation yield using HPLC at different times of conjugation reaction. The molar ratios (antibody: 
Chelator) of 1:3 and 1:5 were found to yield optimum conjugations after reacting the chelate and 
antibody for 24 hours at 37°C.  
  The molar ratios of 1:3 and 1:5 were adopted for subsequent radiolabeling experiments. 
Anti-SAS1B antibody SB2 was radiolabeled with different levels radioactivity of 67Cu radionuclide. 
There was less uptake of [67Cu]-DOTA and free 67CuCl2 in SNU539 cells than that of the 




the higher uptake of the radiolabeled SB2 is due to binding of SB2 antibody to its SAS1B target. 
Correlation between radiolabeled uptake and SAS1B expression would be useful to show binding 
specificity. 
The biodistribution of both [67Cu]-DOTA and free [67Cu]-Cl2 were also determined. 
Compared to antibody, these are small molecules and are cleared rapidly from the blood with 
subsequent clearance by kidney and, to some extent, by hepatobiliary excretion. This could be due 
to the slow [67Cu]-DOTA metabolism in liver [158].  
  Free 67Cu biodistribution also showed fast clearance by the kidneys after 6 hours, which is 
matched by corresponding activity in the urine. Activity in the liver is indicative of copper 
metabolism in the liver and also binding to cerepruplasmin, a copper binding protein [159]. Further 
experiments with different cells lines do not express SAS1B surface antigen is required to 
investigate the significance of radiolabeled SB2 targeting SNU539 cells. As mentioned before, there 
are many factors contributing to cell uptake and competeting the binding of antibody to target 
antigen. These include, linking the chelator to antibody and the effect of radiation on the nature of 
the antibody when it’s labeled with radionuclides. 
   Ex vivo preliminary experiments were done before in vivo imaging to reveal organ-based uptake. 











5.3 Labeling SB2 with NIRdye800CW 
 
                  Near infra-red dye800CW was used to label antiSAS1B SB2 or in vitro experiments. 
Therefore, optimizing of antibody to dye (SB2-IR800CW) conjugation was done first to determine 
the optimal ratio of conjugation. Then, the optimal conjugation ratio of SB2-to-IR800CW was used 
for in vitro work. 
5.3.1 SB2-IRdye800CW Conjugation. 
 
Anti-SAS1B (SB2) was conjugated to IR800CW in different molar ratios 1:1, 1:2 and 1:3 and 
analyzed using UV/Vis systems. Absorptions and emissions of SB2-IR800CW were determined 
(Figure 32A). The absorption and emission spectra of SB2-IRD800CW matches the absorption and 
emission spectra of IR800CW dye from Licor (Figure32B). Figure 33 shows the absorption of SB2-
IR800CW ratio 1:3. The absorption of SB2-IR800CW increases about two-fold from ratio 1:1 to 
1:2, whereas, the molar ratio 1:3 of SB2-IR800CW increased to one-fold from ratio 1:2 (Figure 34).   
                       
Figure 32-A. Absorption                                                   Figure 32 B-. Spectra of NIRDye 800C       





















SB2 & Dye  
 
 














5.3.2 Conjugation Stability  
 
 Stabilty of SB2 &IRDye 800CW conjugations in different ratios and the unconjugated dye 
IRdye800CW were  monitored for a period of 5 days using UV/Vis spectrophotometer. There was 
steady slight dercreasing of fluorescent signal over time for both SB2&dye and the unconjugated 
dye (Figure 35) . The conjugated SB2 was stored at 4°C with protection from the light during this 
time. 
 
Figure 35. Antibody SB2 -IR800CW stabilty. Absorbances of three ratios of SB2-IR800CW (1:1, 




5.3.3 Cell Binding 
 
                 Three different cell lines were grown in two 6-well culture plates. Two of these cell lines 
were SNU539 and SKOV3 which express SAS1B surface antigen and the other one is A549 cell 
lines (lung cell lines) which does not expess SAS1B. These cells were incubated with SB2 labeled 
with IR800CW in one 6-well plates for one hour at 37°C and the same type of cells in another 6-




control. This followed by washing the cells with saline to remove any unbinded labeled SB2, IgG or 
dye.These cells were examined using fluoresence microscpe (Figure 36). 
Near infra-red dye signals were seen in SNU539 and SKOV3 cell lines which incubated with SB2-
IR800CW while no signal was seen from A549 cells. Also, there were no fluorsence signals when 
the cells incubated with IgG-IR800CW. This illistrated that there was binding of SB2-IR800CW 
with SAS1B surface antgen expresed by SNU539 and SK-OV3. 
 Cancer cell lines              IgG-IR800CW              SB2-IR800CW 
     
SNU539            
                                                                                                                                            
SK-OV3  
       
A549  
   Figure 36.Three different cells, SNU539 uterine cancer cells, SK-OV3 ovarian cancer cell, and 
A549 lung cancer cell. These cells were treated with SB2 labeled with IR800CW and IgG labeled 
with IR800CW. Both SNU539 and SK-OV are expressing SAS1B but A549 does not express 












            Near-infrared dye was chosen as an alternative to radioactive agents to labeled anti-SAS1B 
(SB2) as an image guide for tumor localization and Biodistribution study. Near infra-red dye 
800CW-NHS ester was prepared according to good manufacturing guidelines [160].  Optimization 
of antiSAS1B SB2 with IRDye800CW-NHS ester conjugation  was performed to obtain the optimal 
ratio that could be used in vitro and in vivo and determine high fluoresce signal less background 
noise, decrease the effect of antibody-antigen binding, and reduce dye toxicity due to the excess of 
dye [161]. Optimization of SB2-IR800CW was done by reacting different molar ratios (antibody: 
Dye) 1:1, 1:2 and 1:3 in phosphate –buffered saline (PBS, pH 8.3) solution. The results of UV/Vis 
analyzer showed the ratio 1:2 of SB2 to dye conjugation represent a good signal with less 
detachment of dye to antibody because when the ratio was increased to 1:3, the intensity increased 
just to one-fold by comparing the intensities of 1:1 and 1:2 ratios. The ratio 1:2 of conjugation was 
used for in vitro and in vivo studies.  
In vitro study was done by determining the fluorescence signals which were produced after 
incubating SB2-IR800CW with SNU539 and SK-OV3 cell lines which are expressing SAS1B and 
compared to fluorescence signals produced when incubating the same cell lines with nonspecific 
antibody IgG labeled with IR800CW.  Additionally, different cell lines A549 (cancer cell lines) 
were incubated with SB2-IR800CW and IgG-IR800CW. Fluorescence signals were determined 
using fluorescence microscope and the results showed some signals were produced from SNU539 
and SK-OV3 cells that were incubated with SB2-IR800CW. There were no signals from the same 
types of cells incubated with IgG-IR800CW. Moreover, there was no fluorescence signal produced 
by A549 cell lines. This confirms that there was specific binding of SB2-IR800CW to SAS1B 






























6.1 Radiolabeling of SB2/5 with 89Zr 
 
               In this work, two of anti-SAS1B (SB5 and SB2) were radiolabeled with 89Zr and 67Cu 
respectfully. Anti-SAS1B SB2 was also labeled with near-infrared dye 800CW.  The labeling of 
SB5 and SB2 was performed to investigate the in vitro and in vivo binding of both anti-SAS1B to 
uterine cancer surface antigen SAS1B. The over-expression of SAS1B in several types of cancer 
cells, including uterine was a novel discovery by the University of Virginia and is an opportunity for 
tumor receptor imaging which could guide and improve cancer detection and treatment. Labeling 
with 89Zr was preformed based on a substantial number of studies showing promising PET imaging 
with 89Zr labeling [162], in addition to 89Zr was available at VCU hospital. 89Zr physical and 
chemical properties are attractive, such as 78.8 hours of half-life which matches antibodies’ half-
lives. Also, 89Zr was classified as a hard cation that binds strongly to the chelator through six hard, 
anionic oxygen donors of Desferrioxamine (DFO) [83]. DFO chelator was chosen as a linker 
between SB5 and 89Zr because it is the preferred chelator for 89Zr labeling and it binds to antibodies 
through the lysine amino acid residues which are available with about 80% on antibodies. 
6.2 SB5-DFO Conjugation 
 
 In order to label SB5 with 89Zr, firstly SB5-DFO conjugate was optimized through many reactions 
with different reaction variables. The optimized conjugation was described in the Methods chapter. 
The conjugation yield of optimized reaction was more than 85%. Conjugation of SB5 with DFO was 
evaluated using HPLC through a size exclusion column where the qualitative and quantitative yields 
of conjugation can be determined. This conjugation yield was encouraging compared with other 
studies for 89Zr labeling antibodies. Optimization of antibody conjugation with chelators takes time 




could not be ordered unless good optimization was performed because of the decay of radioactive 
isotope and it is also expense. 
6.3 89Zr-DFO-SB5 
 
Once the conjugations of SB5 with DFO were optimized, 89Zr was ordered for labeling SB5-
DFO. Different labeling reactions were performed and the optimized procedures resulted in an 
average yield of 67±8%. Other studies with 89Zr-DFO antibody labeling reported similar yield after 
purifications [163] . The results of HPLC chromatograph showed some fragmentation of SB2. This 
might be the effect of radioactivity of 89Zr, and needs to be investigated. In order to remove all 
unwanted labeling, the reaction was purified using a size exclusion column PD10. The purified 
fractions were analyzed using radio-TLC, and the highest yield of labeling was used for in vitro and 
in vivo work.  
 6.4 SB2 DOTA Conjugation and [67Cu]-DOTA-SB2 
 
  Optimizing the conjugation of SB2 with DOTA was performed first. Different ratios of SB2-
DOTA were investigated in different conditions of incubation temperature, speed of shaking, and 
reaction time.  The ratios 1:3 and 1:5 showed about 100% of conjugation yield using an HPLC-size 
exclusion column. This reaction was incubated at 37C for 24 hours. This conjugation of SB2-DOTA 
was monitored for one week and was stable at 4C. The conjugated SB2-DOTA with 1:5 molar ratio 
was labeled with 67Cu, in chloride form buffered solution (PH=4-5). Radiolabeling yield reached 
85% and following PD10 purification, a radiochemical purity of more than 95% was achieved. This 







6.5 Evaluation of radiolabeled SB2 and SB5 in cells expressing SAS1B 
 
                All in vitro experiments were done to investigate the binding of SB5-DFO-[89Zr], SB2-
DOTA- [67Cu] and labeled SB2 with NIR dye 800CW to SAS1B uterine cancer cell surface antigen. 
All results showed the specific binding of labeled anti-SAS1B antibodies to its target SAS1B. 
SNU539 cells in different numbers were incubated with labeling SB5with 89Zr for 2 hours and then 
washed to remove any unbinding species. The radioactivity associated with cells was measured and 
the results show the radioactivity increased when the cell number of SNU539 was increased. This 
indicates the binding of radiolabeled SB5 to expressed SAS1B on SNU539 cells.   
While the in vitro work of radiolabeled SB2 with 67Cu, SB2 was labeled with 4uCi of 67Cu 
and incubated with SNU539 and SK-OV3 and similar radioactivity of 67Cucl2 and DOTA-[67Cu] 
were also incubated with SNU539 cell line. After washing all cells, the radioactivity measures 
showed high uptake of SB2-DOTA-[67Cu] for both SNU539 and SK-OV3 cells compared to the 
uptake of 67Cu and DOTA-[67Cu] p value <0.05. Both SNU539 and Sk-OV3 cell line express 
SAS1B which indicate the specific binding of radiolabeled SB2 to SAS1B.  
 6.7 In Vivo imaging and Biodistribution. 
 
           After confirming the specific binding of labeled anti-SAS1B antibodies to its target SAS1B, 
in vivo and ex vivo work were done to determine tumor uptake and biodistribution. The in vivo 
experiments include culturing cell lines, monitoring cell growth, assessing cell viability, and the cell 
were harvested and inoculated subcutaneously into the mice flanks to implement a tumor. All these 
steps took about 3 months because of the slow growth of SNU539 cell line. When tumor animal 
model was prepared for [89Zr]-DFO-SB5 experiments, [89Zr]-DFO-SB5 was injected in a female 
mouse bearing tumor and the PET images of the mouse were taken at different periods of time. The 




organs. More uptake was shown in bone, liver, and spleen after 72 hours while less uptake by the 
tumor. Also, more bone uptake of 89Zr was reported in a number of studies [153]. In addition, high 
radioactivity can affect the immunoreactivity. The HPLC chromatogram results also showed small 
peaks which might be SB5 fragments due to the effects of radioactivity of 89Zr. The ex vivo results 
illustrated the biodistribution of radioactivity in each organ. The ex vivo results were similar the PET 
scan results, less uptake by the tumor compared to other organs. In addition, high levels of 
radioactivity were determined in the bone, spleen, and liver. Radioactivity of [89Zr]-DFO-SB5 
toward SAS1B expressed by uterine tumor was noticeable compared with the uptake of nonspecific 
antibody [89Zr]-DFO-3A4. 
It is important to know the accumulation profile of radiolabeled components that make up 
the radio-conjugate, such as 67CuCl2 and [67Cu]-DOTA. In this regard, ex vivo experiments using 
67Cu were performed to study the biodistribution of 67CuCl2 and [67Cu]-DOTA in animals.  In this 
experiment, two groups of mice were used.One group was injected with 67Cu only and the other 
group was injected with [67Cu]-DOTA.  In triplicate mice were sacrificed at different time points 
and organs were collected. The radioactivity of each organ was determined after normalizing all 
date. Biodistribution results showed rapid clearing of both 67Cu and [67Cu]-DOTA after 6 hours, 
except in the liver which slowed accumulation and slow clearance of 67Cu and [67Cu]-DOTA. This 
could be due to cooper interaction and metabolism in the liver. 
6.8 Fluorescence microscopy of SB2 labeled with near-infrared dye 800CW 
 
 Near-infrared dye was used as alternative to radiolabeling. In this work, SB2 was labeled 
with the dye in different ratio (1:1, 1:2 and 1:3). This was done to determine the labeling yield of 
different molar ratios. Results showed the increases for fluorescent signal to about 2 folds from ratio 




dye to lysine residues on the antibody[164]. The stability of all ratios of labeled SB2 to dye was 
monitored using UV/Vis analyzer for 5 days and compared to the stability of the dye only. The 
results showed that the fluorescent signals are decreasing slowly with the time. The molar ratio 1:3 
of SB2 to dye was used for in vitro work to determine the binding of non-radioactive labeled SB2 to 
SAS1B. Different cell lines SNU539, SK-OV3 and A549 were grown and incubated with SB2-
INRdye 800CW. Fluorescent signals were determined on SNU539 and SK-OV3 cells while no 
signals on A549. These fluorescent signals indicate the binding of SB2 to SAS1B on SNU539 and 
SK-OV3 due to the overexpression of SAS1B on these cell as reported in the UVA studies. The lung 
cells A549 were used as negative control and there were no fluorescent signals determined on these 
cells. Near-infrared labeling of SB2 confirms the specific binding of SB2 to its target SAS1B and 
the results are encouraging for in vivo study of imaging uterine tumor and biodistribution in mouse 
model. With this fluorescence labeling version of monoclonal, it is a useful additional 










































7.1 Summary   
 
Radiolabeling anti-SAS1B antibodies with 89Zr, 67Cu and near-infrared dye 800CW have 
been synthesized to enable molecular imaging of the radiolabeled conjugates in uterine cancer 
xenografts expressing the cell surface antigen SAS1B. 
Optimizing the conjugation of the chelators of radioactive isotopes with anti-SAS1B (SB2 
and SB5) and SB2 with near-infrared was performed using low scale of activity. HPLC with size 
exclusion chromatography was used to determine the conjugation yield and radiochemical purity. 
Radiolabeled yields of SB5 and SB2 were determined using radio-TLC analysis and then purified 
using size exclusion column PD10. Labeling SB2 with near-infrared dye was determined by 
UV/VIS fluorescence microscopy. In vitro study confirmed the specific binding of SB2 and SB5 to 
SAS1B receptor on uterine cancer cell lines SNU539. 
In vivo PET imaging of 89Zr-radiolabeled SB5, in tumor-bearing nude mice, showed some 
radioactivity in the tumor, indicative of preferential accumulation, presumably due to affinity of 
radiolabeled SB5 toSAS1B present on surface of tumor cells. However, conformation of binding 
specificity needs to be assessed by relating radiolabeled SB5 uptake to level of SAS1B present on 
the same tumor. Significant uptake was also observed in bone, a phenomenon that has been reported 
in the literature of 89Zr-immunoPET imaging [165]. The explanation for bone accumulation is 
probably due to detachment of the radioisotope from its DFO cage and as zirconium has affinity for 
the phosphonate lattice, it accumulates in bone. Chelators other than DFO are being developed in an 
attempt to reduce in vivo instability, for example the linker HOPO [166]. 
Preliminary in vitro experiments of radiolabeled SB2 with 67Cu demonstrated the specific 
uptake of both the uterine cancer cell line SNU539 and ovarian cancer cell line SK-OV3 because 
both cell lines express SAS1B. The use of [67Cu]-DOTA SB2 for future in vivo studies may provide 




with the NIR dye 800CW could also be used in validation experiments as it was established that this 
optical probe showed uptake of both cells SNU539 and SK-OV3 which express SAS1B compared to 
a negative control, the lung cancer cell line A549 which does express SAS1B. 
7.2 Future work 
 
Future work should build on the progress made in the development of radio-immuno-conjugates and 
pursue three future aims: 
1. Further optimize [64/67Cu]-SB2/5 conjugation and investigate its stability, particularly in 
vivo, by performing radio-HPLC analysis on homogenized tissues, including tumors. 
2. Determine the amount of SAS1B in tumor sections by protein assay, and assess how this 
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